{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd\n",
    "import numpy as np\n",
    "from PyPDF2 import PdfReader\n",
    "import re"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Unnamed: 0</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>[HEAD]\\nWhen your patient presents with modera...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>[VISUAL COPY/DISCLAIMER] [ART NOTE: appears wi...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>[SUBHEAD]  [Leveraged from eFile 121146]\\nHEAD...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>[COPY]\\nIn a phase 3, multicentre, randomized,...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>&lt;“PASI 90” icon&gt; TREMFYA® demonstrated a super...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                          Unnamed: 0\n",
       "0  [HEAD]\\nWhen your patient presents with modera...\n",
       "1  [VISUAL COPY/DISCLAIMER] [ART NOTE: appears wi...\n",
       "2  [SUBHEAD]  [Leveraged from eFile 121146]\\nHEAD...\n",
       "3  [COPY]\\nIn a phase 3, multicentre, randomized,...\n",
       "4  <“PASI 90” icon> TREMFYA® demonstrated a super..."
      ]
     },
     "execution_count": 2,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "claims = pd.read_excel(r'data\\Tremfya_email_claims.xlsx')\n",
    "claims.head()\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Unnamed: 0</th>\n",
       "      <th>text</th>\n",
       "      <th>reference</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>[HEAD]\\nWhen your patient presents with modera...</td>\n",
       "      <td>When your patient presents with moderate-to-se...</td>\n",
       "      <td>[PM p. 4A]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>[VISUAL COPY/DISCLAIMER] [ART NOTE: appears wi...</td>\n",
       "      <td>TREMFYA®/TREMFYA ONE-PRESS® (guselkumab inject...</td>\n",
       "      <td>[PM p. 4A]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>[SUBHEAD]  [Leveraged from eFile 121146]\\nHEAD...</td>\n",
       "      <td>HEAD-TO-HEAD RESULTS: TREMFYA® 48-WEEK EFFICAC...</td>\n",
       "      <td>[ECLIPSE p 5A, 5B, 6A]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>[COPY]\\nIn a phase 3, multicentre, randomized,...</td>\n",
       "      <td>In a phase 3, multicentre, randomized, double-...</td>\n",
       "      <td>[COPY]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>&lt;“PASI 90” icon&gt; TREMFYA® demonstrated a super...</td>\n",
       "      <td>&lt;“PASI 90” icon&gt; TREMFYA® demonstrated a super...</td>\n",
       "      <td>[ECLIPSE p 5A, 5B, 6A]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>[CALL-OUT] [ART NOTE: Distinct visual separati...</td>\n",
       "      <td>TREMFYA®: THE FIRST IL-23 INHIBITOR WITH INDIC...</td>\n",
       "      <td>[DOF Letter, March 2, 2021, p1A]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>[HIGH LEVEL BALANCE]\\nIndication not previousl...</td>\n",
       "      <td>Indication not previously mentioned and clinic...</td>\n",
       "      <td>[PM p. 4B]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>Do not initiate treatment in patients with any...</td>\n",
       "      <td>Do not initiate treatment in patients with any...</td>\n",
       "      <td>[PM p. 7A]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>Discontinue treatment if patient develops a se...</td>\n",
       "      <td>Discontinue treatment if patient develops a se...</td>\n",
       "      <td>[PM p. 7B]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>Evaluate patients for tuberculosis infection p...</td>\n",
       "      <td>Evaluate patients for tuberculosis infection p...</td>\n",
       "      <td>[PM p. 7C]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>Consider completion of all immunizations prior...</td>\n",
       "      <td>Consider completion of all immunizations prior...</td>\n",
       "      <td>[PM p. 7D]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>Concurrent use with live vaccines is not recom...</td>\n",
       "      <td>Concurrent use with live vaccines is not recom...</td>\n",
       "      <td>[PM p. 7D]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>Discontinue treatment in cases of serious hype...</td>\n",
       "      <td>Discontinue treatment in cases of serious hype...</td>\n",
       "      <td>[PM p. 8A]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>Women of childbearing potential should use ade...</td>\n",
       "      <td>Women of childbearing potential should use ade...</td>\n",
       "      <td>[PM p. 8D]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>Use during pregnancy only if clearly needed [P...</td>\n",
       "      <td>Use during pregnancy only if clearly needed</td>\n",
       "      <td>[PM p. 8D]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>The benefits of breastfeeding should be consid...</td>\n",
       "      <td>The benefits of breastfeeding should be consid...</td>\n",
       "      <td>[PM p. 8A]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>Effect on human fertility has not been evaluat...</td>\n",
       "      <td>Effect on human fertility has not been evaluated</td>\n",
       "      <td>[PM p. 8B]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>Safety and efficacy in pediatric patients have...</td>\n",
       "      <td>Safety and efficacy in pediatric patients have...</td>\n",
       "      <td>[PM p. 9B]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>Data in patients ≥65 years of age are limited ...</td>\n",
       "      <td>Data in patients ≥65 years of age are limited</td>\n",
       "      <td>[PM p. 9C]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>Patients were ≥18 years with moderate-to-sever...</td>\n",
       "      <td>Patients were ≥18 years with moderate-to-sever...</td>\n",
       "      <td>[ECLIPSE p. 3A, p. 3B, p. 3C, p. 4A]</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                           Unnamed: 0  \\\n",
       "0   [HEAD]\\nWhen your patient presents with modera...   \n",
       "1   [VISUAL COPY/DISCLAIMER] [ART NOTE: appears wi...   \n",
       "2   [SUBHEAD]  [Leveraged from eFile 121146]\\nHEAD...   \n",
       "3   [COPY]\\nIn a phase 3, multicentre, randomized,...   \n",
       "4   <“PASI 90” icon> TREMFYA® demonstrated a super...   \n",
       "5   [CALL-OUT] [ART NOTE: Distinct visual separati...   \n",
       "6   [HIGH LEVEL BALANCE]\\nIndication not previousl...   \n",
       "7   Do not initiate treatment in patients with any...   \n",
       "8   Discontinue treatment if patient develops a se...   \n",
       "9   Evaluate patients for tuberculosis infection p...   \n",
       "10  Consider completion of all immunizations prior...   \n",
       "11  Concurrent use with live vaccines is not recom...   \n",
       "12  Discontinue treatment in cases of serious hype...   \n",
       "13  Women of childbearing potential should use ade...   \n",
       "14  Use during pregnancy only if clearly needed [P...   \n",
       "15  The benefits of breastfeeding should be consid...   \n",
       "16  Effect on human fertility has not been evaluat...   \n",
       "17  Safety and efficacy in pediatric patients have...   \n",
       "18  Data in patients ≥65 years of age are limited ...   \n",
       "19  Patients were ≥18 years with moderate-to-sever...   \n",
       "\n",
       "                                                 text  \\\n",
       "0   When your patient presents with moderate-to-se...   \n",
       "1   TREMFYA®/TREMFYA ONE-PRESS® (guselkumab inject...   \n",
       "2   HEAD-TO-HEAD RESULTS: TREMFYA® 48-WEEK EFFICAC...   \n",
       "3   In a phase 3, multicentre, randomized, double-...   \n",
       "4   <“PASI 90” icon> TREMFYA® demonstrated a super...   \n",
       "5   TREMFYA®: THE FIRST IL-23 INHIBITOR WITH INDIC...   \n",
       "6   Indication not previously mentioned and clinic...   \n",
       "7   Do not initiate treatment in patients with any...   \n",
       "8   Discontinue treatment if patient develops a se...   \n",
       "9   Evaluate patients for tuberculosis infection p...   \n",
       "10  Consider completion of all immunizations prior...   \n",
       "11  Concurrent use with live vaccines is not recom...   \n",
       "12  Discontinue treatment in cases of serious hype...   \n",
       "13  Women of childbearing potential should use ade...   \n",
       "14        Use during pregnancy only if clearly needed   \n",
       "15  The benefits of breastfeeding should be consid...   \n",
       "16   Effect on human fertility has not been evaluated   \n",
       "17  Safety and efficacy in pediatric patients have...   \n",
       "18      Data in patients ≥65 years of age are limited   \n",
       "19  Patients were ≥18 years with moderate-to-sever...   \n",
       "\n",
       "                               reference  \n",
       "0                             [PM p. 4A]  \n",
       "1                             [PM p. 4A]  \n",
       "2                 [ECLIPSE p 5A, 5B, 6A]  \n",
       "3                                 [COPY]  \n",
       "4                 [ECLIPSE p 5A, 5B, 6A]  \n",
       "5       [DOF Letter, March 2, 2021, p1A]  \n",
       "6                             [PM p. 4B]  \n",
       "7                             [PM p. 7A]  \n",
       "8                             [PM p. 7B]  \n",
       "9                             [PM p. 7C]  \n",
       "10                            [PM p. 7D]  \n",
       "11                            [PM p. 7D]  \n",
       "12                            [PM p. 8A]  \n",
       "13                            [PM p. 8D]  \n",
       "14                            [PM p. 8D]  \n",
       "15                            [PM p. 8A]  \n",
       "16                            [PM p. 8B]  \n",
       "17                            [PM p. 9B]  \n",
       "18                            [PM p. 9C]  \n",
       "19  [ECLIPSE p. 3A, p. 3B, p. 3C, p. 4A]  "
      ]
     },
     "execution_count": 3,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# using regex extract all text not between []\n",
    "ext_claims = []\n",
    "ext_refs = []\n",
    "for i in range(len(claims)):\n",
    "    my_str = claims.iloc[i].squeeze()\n",
    "    ext_claims.append(re.sub(r'\\[.*?\\]', '', my_str))\n",
    "    ext_refs.append(re.findall(r'\\[.*?\\]', my_str)[-1])\n",
    "\n",
    "claims['text'] = ext_claims\n",
    "claims['text'] = claims['text'].str.replace('\\n', '').str.strip()\n",
    "claims['reference'] = ext_refs\n",
    "claims"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "TRE11082022CPM_SNDS 259046.docx\n",
      "EDMS -ERI-121169578 v15.0 Page 4of 47PART I: HEA LTH PROFESSIONA L INFORMA TION\n",
      "1INDICA TIONS\n",
      "Plaque Psoriasis\n",
      "TREMFYA®/TREMFYA One -Press®(guselkumab injection) is indicated for:\n",
      "the treatment of adult patients with moderate -to-severe plaque psoriasis who are \n",
      "candidates for systemic therapy or phototherapy. \n",
      "Psoriatic A rthritis\n",
      "TREMFYA®/TREMFYA One -Press®(guselkumab injection) is indicated for: \n",
      "the treatment of adult patients wit h active psoriatic arthritis. TREMFYA®/TREMFYA One -\n",
      "Press®can be used alone or in combination with a conventional disease -modifying \n",
      "antirheumatic drug (cDMARD) (e.g., methotrexate).\n",
      "1.1 Pediatrics\n",
      "The safety and efficacy of TREMFYA®/TREMFYA One -Press®in pediatric patients have not \n",
      "been evaluated.\n",
      "1.2 Geriatrics\n",
      "Of the 3406 plaque psoriasis and psoriatic arthritis patients exposed to TREMFYA®/TREMFYA \n",
      "One-Press®in Phase 2 and Phase 3 clinical trials, a limited number of patients were 65 years or \n",
      "older (n = 185, 5%) or 75 years and older (n=13, 0.4%). Thus, data in these age groups are \n",
      "limited (see 10 CLINICA L PHA RMACOLOGY ).\n",
      "2CONTRA INDICA TIONS\n",
      "TREMFYA®/TREMFYA One -Press®is contraindicated in patients with known serious \n",
      "hypersensitivity to guselkumab or any of the components. For a complete listing of components, \n",
      "see the 6 DOSA GE FORMS, STRENGTHS, COMPOSITION A ND PA CKAGING section.\n",
      "4DOSA GE AND ADMINISTR ATION\n",
      "TREMFYA®/TREMFYA One-Press®is administered by subcutaneous injection.\n",
      "4.1 Dosing Considerations\n",
      "TREMFYA®/TREMFYA One -Press®is intended for use under the guidance and supervision of a \n",
      "physician. \n",
      "TREMFYA®/TREMFYA One -Press®may be administered by a healthcare professional, or a \n",
      "patient or caregiver may administer the injection after proper training in subcutaneous injection \n",
      "technique. \n",
      "4.2 Recommended Dose and Dosage A djustment\n",
      "Plaque psoriasis\n",
      "The recommended dose of TREMFYA®/TREMFYA One -Press®is 100 mg to be given as \n"
     ]
    }
   ],
   "source": [
    "# Let's read page 4 of the pdf\n",
    "reader = PdfReader('data/MASTER_TremfyaPM_08Nov2022_annotated.pdf')\n",
    "page = reader.pages[3]\n",
    "print(page.extract_text())"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "> Playing around with some spacy -- probably not needed at this stage"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['TRE11082022CPM_SNDS 259046.docx\\nEDMS -ERI-121169578 v15.0 Page 4of 47PART I: HEA LTH PROFESSIONA L INFORMA TION\\n1INDICA TIONS\\nPlaque Psoriasis\\nTREMFYA®/TREMFYA One -Press®(guselkumab injection) is indicated for:\\n\\uf0b7the treatment of adult patients with moderate -to-severe plaque psoriasis who are \\ncandidates for systemic therapy or phototherapy. \\nPsoriatic A rthritis\\nTREMFYA®/TREMFYA One -Press®(guselkumab injection) is indicated for: \\n\\uf0b7the treatment of adult patients wit h active psoriatic arthritis. TREMFYA®/TREMFYA One -\\nPress®can be used alone or in combination with a conventional disease -modifying \\nantirheumatic drug (cDMARD) (e.g., methotrexate)',\n",
       " '1.1 Pediatrics\\nThe safety and efficacy of TREMFYA®/TREMFYA One -Press®in pediatric patients have not \\nbeen evaluated',\n",
       " '1.2 Geriatrics\\nOf the 3406 plaque psoriasis and psoriatic arthritis patients exposed to TREMFYA®/TREMFYA \\nOne-Press®in Phase 2 and Phase 3 clinical trials, a limited number of patients were 65 years or \\nolder (n = 185, 5%) or 75 years and older (n=13, 0.4%). Thus, data in these age groups are \\nlimited (see 10 CLINICA L PHA RMACOLOGY )',\n",
       " '2CONTRA INDICA TIONS\\nTREMFYA®/TREMFYA One -Press®is contraindicated in patients with known serious \\nhypersensitivity to guselkumab or any of the components. For a complete listing of components, \\nsee the 6 DOSA GE FORMS, STRENGTHS, COMPOSITION A ND PA CKAGING section',\n",
       " '4DOSA GE AND ADMINISTR ATION\\nTREMFYA®/TREMFYA One-Press®is administered by subcutaneous injection',\n",
       " '4.1 Dosing Considerations\\nTREMFYA®/TREMFYA One -Press®is intended for use under the guidance and supervision of a \\nphysician. \\nTREMFYA®/TREMFYA One -Press®may be administered by a healthcare professional, or a \\npatient or caregiver may administer the injection after proper training in subcutaneous injection \\ntechnique. \\n4.2 Recommended Dose and Dosage A djustment\\nPlaque psoriasis\\nThe recommended dose of TREMFYA®/TREMFYA One -Press®is 100 mg to be given as ']"
      ]
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "page.extract_text().split('.\\n')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['TRE11082022CPM_SNDS 259046.docx EDMS -ERI-121169578 v15.0 Page 4of 47PART I: HEA LTH PROFESSIONA L INFORMA TION 1INDICA TIONS Plaque Psoriasis TREMFYA®/TREMFYA One -Press®(guselkumab injection) is indicated for: \\uf0b7the treatment of adult patients with moderate -to-severe plaque psoriasis who are  candidates for systemic therapy or phototherapy.  Psoriatic A rthritis TREMFYA®/TREMFYA One -Press®(guselkumab injection) is indicated for:  \\uf0b7the treatment of adult patients wit h active psoriatic arthritis. TREMFYA®/TREMFYA One - Press®can be used alone or in combination with a conventional disease -modifying  antirheumatic drug (cDMARD) (e.g., methotrexate)',\n",
       " '1.1 Pediatrics The safety and efficacy of TREMFYA®/TREMFYA One -Press®in pediatric patients have not  been evaluated',\n",
       " '1.2 Geriatrics Of the 3406 plaque psoriasis and psoriatic arthritis patients exposed to TREMFYA®/TREMFYA  One-Press®in Phase 2 and Phase 3 clinical trials, a limited number of patients were 65 years or  older (n = 185, 5%) or 75 years and older (n=13, 0.4%). Thus, data in these age groups are  limited (see 10 CLINICA L PHA RMACOLOGY )',\n",
       " '2CONTRA INDICA TIONS TREMFYA®/TREMFYA One -Press®is contraindicated in patients with known serious  hypersensitivity to guselkumab or any of the components. For a complete listing of components,  see the 6 DOSA GE FORMS, STRENGTHS, COMPOSITION A ND PA CKAGING section',\n",
       " '4DOSA GE AND ADMINISTR ATION TREMFYA®/TREMFYA One-Press®is administered by subcutaneous injection',\n",
       " '4.1 Dosing Considerations TREMFYA®/TREMFYA One -Press®is intended for use under the guidance and supervision of a  physician.  TREMFYA®/TREMFYA One -Press®may be administered by a healthcare professional, or a  patient or caregiver may administer the injection after proper training in subcutaneous injection  technique.  4.2 Recommended Dose and Dosage A djustment Plaque psoriasis The recommended dose of TREMFYA®/TREMFYA One -Press®is 100 mg to be given as ']"
      ]
     },
     "execution_count": 7,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "[part.replace('\\n', ' ') for part in page.extract_text().split('.\\n')]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [],
   "source": [
    "# manually cleaned it a bit to make sure headlines are separated\n",
    "corpus = [\n",
    "'TRE11082022CPM_SNDS 259046.docx EDMS -ERI-121169578 v15.0 Page 4of 47',\n",
    "'PART I: HEALTH PROFESSIONAL INFORMATION 1 INDICATIONS',\n",
    "'Plaque Psoriasis TREMFYA®/TREMFYA One -Press®(guselkumab injection) is indicated for: the treatment of adult patients with moderate -to-severe plaque psoriasis who are  candidates for systemic therapy or phototherapy.',\n",
    "'Psoriatic A rthritis TREMFYA®/TREMFYA One -Press®(guselkumab injection) is indicated for:  the treatment of adult patients wit h active psoriatic arthritis. TREMFYA®/TREMFYA One - Press®can be used alone or in combination with a conventional disease -modifying  antirheumatic drug (cDMARD) (e.g., methotrexate)',\n",
    "'1.1 Pediatrics The safety and efficacy of TREMFYA®/TREMFYA One -Press®in pediatric patients have not  been evaluated',\n",
    "'1.2 Geriatrics Of the 3406 plaque psoriasis and psoriatic arthritis patients exposed to TREMFYA®/TREMFYA  One-Press®in Phase 2 and Phase 3 clinical trials, a limited number of patients were 65 years or  older (n = 185, 5%) or 75 years and older (n=13, 0.4%). Thus, data in these age groups are  limited (see 10 CLINICA L PHA RMACOLOGY )',\n",
    "'2 CONTRA INDICATIONS TREMFYA®/TREMFYA One -Press®is contraindicated in patients with known serious  hypersensitivity to guselkumab or any of the components. For a complete listing of components,  see the 6 DOSA GE FORMS, STRENGTHS, COMPOSITION A ND PA CKAGING section',\n",
    "'4 DOSAGE AND ADMINISTR ATION TREMFYA®/TREMFYA One-Press®is administered by subcutaneous injection',\n",
    "'4.1 Dosing Considerations TREMFYA®/TREMFYA One -Press®is intended for use under the guidance and supervision of a  physician.  TREMFYA®/TREMFYA One -Press®may be administered by a healthcare professional, or a  patient or caregiver may administer the injection after proper training in subcutaneous injection  technique.  4.2 Recommended Dose and Dosage A djustment Plaque psoriasis The recommended dose of TREMFYA®/TREMFYA One -Press®is 100 mg to be given as '\n",
    "]"
   ]
  },
  {
   "attachments": {
    "image.png": {
     "image/png": "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"
    }
   },
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## A sample of the original pdf page:\n",
    "\n",
    "![image.png](attachment:image.png)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Unnamed: 0</th>\n",
       "      <th>text</th>\n",
       "      <th>reference</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>[HEAD]\\nWhen your patient presents with modera...</td>\n",
       "      <td>When your patient presents with moderate-to-se...</td>\n",
       "      <td>[PM p. 4A]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>[VISUAL COPY/DISCLAIMER] [ART NOTE: appears wi...</td>\n",
       "      <td>TREMFYA®/TREMFYA ONE-PRESS® (guselkumab inject...</td>\n",
       "      <td>[PM p. 4A]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>[HIGH LEVEL BALANCE]\\nIndication not previousl...</td>\n",
       "      <td>Indication not previously mentioned and clinic...</td>\n",
       "      <td>[PM p. 4B]</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                          Unnamed: 0  \\\n",
       "0  [HEAD]\\nWhen your patient presents with modera...   \n",
       "1  [VISUAL COPY/DISCLAIMER] [ART NOTE: appears wi...   \n",
       "6  [HIGH LEVEL BALANCE]\\nIndication not previousl...   \n",
       "\n",
       "                                                text   reference  \n",
       "0  When your patient presents with moderate-to-se...  [PM p. 4A]  \n",
       "1  TREMFYA®/TREMFYA ONE-PRESS® (guselkumab inject...  [PM p. 4A]  \n",
       "6  Indication not previously mentioned and clinic...  [PM p. 4B]  "
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "this_page_claims = claims.iloc[[0,1,6], :]\n",
    "display(this_page_claims)\n",
    "queries = this_page_claims['text'].tolist()\n",
    "# these are the claims we want to match from the email data"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Sentence-BERT\n",
    "\n",
    "https://arxiv.org/abs/1908.10084\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\n",
      "======================\n",
      "\n",
      "\n",
      "Query: When your patient presents with moderate-to-severe plaque psoriasis, SAY TREMFYA®2\n",
      "\n",
      "Top 5 most similar sentences in corpus:\n",
      "1.2 Geriatrics Of the 3406 plaque psoriasis and psoriatic arthritis patients exposed to TREMFYA®/TREMFYA  One-Press®in Phase 2 and Phase 3 clinical trials, a limited number of patients were 65 years or  older (n = 185, 5%) or 75 years and older (n=13, 0.4%). Thus, data in these age groups are  limited (see 10 CLINICA L PHA RMACOLOGY ) (Score: 0.7980)\n",
      "Plaque Psoriasis TREMFYA®/TREMFYA One -Press®(guselkumab injection) is indicated for: the treatment of adult patients with moderate -to-severe plaque psoriasis who are  candidates for systemic therapy or phototherapy. (Score: 0.7039)\n",
      "Psoriatic A rthritis TREMFYA®/TREMFYA One -Press®(guselkumab injection) is indicated for:  the treatment of adult patients wit h active psoriatic arthritis. TREMFYA®/TREMFYA One - Press®can be used alone or in combination with a conventional disease -modifying  antirheumatic drug (cDMARD) (e.g., methotrexate) (Score: 0.6485)\n",
      "4.1 Dosing Considerations TREMFYA®/TREMFYA One -Press®is intended for use under the guidance and supervision of a  physician.  TREMFYA®/TREMFYA One -Press®may be administered by a healthcare professional, or a  patient or caregiver may administer the injection after proper training in subcutaneous injection  technique.  4.2 Recommended Dose and Dosage A djustment Plaque psoriasis The recommended dose of TREMFYA®/TREMFYA One -Press®is 100 mg to be given as  (Score: 0.6127)\n",
      "4 DOSAGE AND ADMINISTR ATION TREMFYA®/TREMFYA One-Press®is administered by subcutaneous injection (Score: 0.5105)\n",
      "\n",
      "\n",
      "======================\n",
      "\n",
      "\n",
      "Query: TREMFYA®/TREMFYA ONE-PRESS® (guselkumab injection) is indicated for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.2\n",
      "\n",
      "Top 5 most similar sentences in corpus:\n",
      "Plaque Psoriasis TREMFYA®/TREMFYA One -Press®(guselkumab injection) is indicated for: the treatment of adult patients with moderate -to-severe plaque psoriasis who are  candidates for systemic therapy or phototherapy. (Score: 0.9552)\n",
      "Psoriatic A rthritis TREMFYA®/TREMFYA One -Press®(guselkumab injection) is indicated for:  the treatment of adult patients wit h active psoriatic arthritis. TREMFYA®/TREMFYA One - Press®can be used alone or in combination with a conventional disease -modifying  antirheumatic drug (cDMARD) (e.g., methotrexate) (Score: 0.9090)\n",
      "2 CONTRA INDICATIONS TREMFYA®/TREMFYA One -Press®is contraindicated in patients with known serious  hypersensitivity to guselkumab or any of the components. For a complete listing of components,  see the 6 DOSA GE FORMS, STRENGTHS, COMPOSITION A ND PA CKAGING section (Score: 0.7799)\n",
      "4 DOSAGE AND ADMINISTR ATION TREMFYA®/TREMFYA One-Press®is administered by subcutaneous injection (Score: 0.7097)\n",
      "4.1 Dosing Considerations TREMFYA®/TREMFYA One -Press®is intended for use under the guidance and supervision of a  physician.  TREMFYA®/TREMFYA One -Press®may be administered by a healthcare professional, or a  patient or caregiver may administer the injection after proper training in subcutaneous injection  technique.  4.2 Recommended Dose and Dosage A djustment Plaque psoriasis The recommended dose of TREMFYA®/TREMFYA One -Press®is 100 mg to be given as  (Score: 0.6708)\n",
      "\n",
      "\n",
      "======================\n",
      "\n",
      "\n",
      "Query: Indication not previously mentioned and clinical use:TREMFYA®/TREMFYA ONE-PRESS® is also indicated for the treatment of adult patients with active psoriatic arthritis. TREMFYA®/TREMFYA ONE-PRESS® can be used alone or in combination with a conventional disease-modifying antirheumatic drug (cDMARD) (e.g., methotrexate).\n",
      "\n",
      "Top 5 most similar sentences in corpus:\n",
      "Psoriatic A rthritis TREMFYA®/TREMFYA One -Press®(guselkumab injection) is indicated for:  the treatment of adult patients wit h active psoriatic arthritis. TREMFYA®/TREMFYA One - Press®can be used alone or in combination with a conventional disease -modifying  antirheumatic drug (cDMARD) (e.g., methotrexate) (Score: 0.9301)\n",
      "Plaque Psoriasis TREMFYA®/TREMFYA One -Press®(guselkumab injection) is indicated for: the treatment of adult patients with moderate -to-severe plaque psoriasis who are  candidates for systemic therapy or phototherapy. (Score: 0.8305)\n",
      "1.2 Geriatrics Of the 3406 plaque psoriasis and psoriatic arthritis patients exposed to TREMFYA®/TREMFYA  One-Press®in Phase 2 and Phase 3 clinical trials, a limited number of patients were 65 years or  older (n = 185, 5%) or 75 years and older (n=13, 0.4%). Thus, data in these age groups are  limited (see 10 CLINICA L PHA RMACOLOGY ) (Score: 0.7654)\n",
      "4.1 Dosing Considerations TREMFYA®/TREMFYA One -Press®is intended for use under the guidance and supervision of a  physician.  TREMFYA®/TREMFYA One -Press®may be administered by a healthcare professional, or a  patient or caregiver may administer the injection after proper training in subcutaneous injection  technique.  4.2 Recommended Dose and Dosage A djustment Plaque psoriasis The recommended dose of TREMFYA®/TREMFYA One -Press®is 100 mg to be given as  (Score: 0.7587)\n",
      "4 DOSAGE AND ADMINISTR ATION TREMFYA®/TREMFYA One-Press®is administered by subcutaneous injection (Score: 0.7415)\n"
     ]
    }
   ],
   "source": [
    "\"\"\"\n",
    "This is a simple application for sentence embeddings: semantic search\n",
    "\n",
    "We have a corpus with various sentences. Then, for a given query sentence,\n",
    "we want to find the most similar sentence in this corpus.\n",
    "\n",
    "This script outputs for various queries the top 5 most similar sentences in the corpus.\n",
    "\"\"\"\n",
    "\n",
    "from sentence_transformers import SentenceTransformer, util\n",
    "import torch\n",
    "\n",
    "embedder = SentenceTransformer(\"all-MiniLM-L6-v2\")\n",
    "\n",
    "\n",
    "corpus_embeddings = embedder.encode(corpus, convert_to_tensor=True)\n",
    "\n",
    "\n",
    "# Find the closest 5 sentences of the corpus for each query sentence based on cosine similarity\n",
    "top_k = min(5, len(corpus))\n",
    "for query in queries:\n",
    "    query_embedding = embedder.encode(query, convert_to_tensor=True)\n",
    "\n",
    "    # We use cosine-similarity and torch.topk to find the highest 5 scores\n",
    "    cos_scores = util.cos_sim(query_embedding, corpus_embeddings)[0]\n",
    "    top_results = torch.topk(cos_scores, k=top_k)\n",
    "\n",
    "    print(\"\\n\\n======================\\n\\n\")\n",
    "    print(\"Query:\", query)\n",
    "    print(\"\\nTop 5 most similar sentences in corpus:\")\n",
    "\n",
    "    for score, idx in zip(top_results[0], top_results[1]):\n",
    "        print(corpus[idx], \"(Score: {:.4f})\".format(score))\n",
    "\n",
    "    \"\"\"\n",
    "    # Alternatively, we can also use util.semantic_search to perform cosine similarty + topk\n",
    "    hits = util.semantic_search(query_embedding, corpus_embeddings, top_k=5)\n",
    "    hits = hits[0]      #Get the hits for the first query\n",
    "    for hit in hits:\n",
    "        print(corpus[hit['corpus_id']], \"(Score: {:.4f})\".format(hit['score']))\n",
    "    \"\"\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'PART I: HEALTH PROFESSIONAL INFORMATION 1 INDICATIONS'"
      ]
     },
     "execution_count": 16,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "corpus[1]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# PART 2: Reading in paper pdf"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Let's read page 4 of the pdf\n",
    "reader = PdfReader('./data/Reich et al. 2019 - ECLIPSE.pdf')\n",
    "page = reader.pages[0]\n",
    "# print(page.extract_text())\n",
    "# write text to file\n",
    "with open('data/ECLIPSE.txt', 'w') as f:\n",
    "    f.write(page.extract_text())"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 44,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "This is a sentence. This is a continuation of the sentence.\n",
      " This is a new paragraph. While one of the other things mentioned is a new paragraph, this is not\n"
     ]
    }
   ],
   "source": [
    "import re\n",
    "\n",
    "# Sample string with '\\n' in the middle of sentences and paragraphs\n",
    "text = \"This is a sentence.\\nThis is a continuation of the sentence.\\n\\nThis is a new paragraph. While one of the other things\\nmentioned is a new paragraph, this is not\"\n",
    "# Replace '\\n' that is not followed by a whitespace or another '\\n'\n",
    "cleaned_text = re.sub(r'\\n(?!\\s|\\n)', ' ', text)\n",
    "\n",
    "print(cleaned_text)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 45,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Articleswww.thelancet.com   Published online August 8, 2019   http://dx.doi.org/10.1016/S0140-6736(19)31773-8  1Guselkumab versus secukinumab for the treatment of  moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial Kristian Reich, April W Armstrong, Richard G Langley, Susan Flavin, Bruce Randazzo, Shu Li, Ming-Chun Hsu, Patrick Branigan, Andrew Blauvelt Summary Background Antibodies targeting interleukin (IL)-23 and IL-17A effectively treat moderate-to-severe psoriasis.  ECLIPSE is the first comparator study of an IL-23p19 inhibitor, guselkumab, versus an IL-17A inhibitor, secukinumab. The primary objective of this study was to show superiority of clinical response at week 48 for guselkumab versus secukinumab. Methods In this phase 3, multicentre, double-blind, randomised, comparator-controlled trial at 142 outpatient  clinical sites in nine countries (Australia, Canada, Czech Republic, France, Germany, Hungary, Poland, Spain, and  the USA), eligible patients were aged 18 years or older, had moderate-to-severe plaque-type psoriasis, and were candidates for phototherapy or systemic therapy. Eligible patients were randomly assigned with permuted block randomisation using an interactive web response system to receive either guselkumab (100 mg at weeks 0 and 4 then every 8 weeks) or secukinumab (300 mg at weeks 0, 1, 2, 3, and 4, and then every 4 weeks). The primary endpoint, the proportion of patients in the intention-to-treat population who achieved 90% reduction or more from baseline of Psoriasis Area and Severity Index (PASI 90 response) at week 48, and major secondary endpoints (the proportions of patients in the guselkumab group and in the secukinumab group who achieved a PASI 75 response at both weeks 12 and 48, a PASI 90 response at week 12, a PASI 75 response at week 12, a PASI 100 response at week 48, an Investigator’s Global Assessment [IGA] score of 0 [cleared] at week 48, and an IGA score of 0 or 1 [minimal] at week 48) were to be tested in a fixed sequence to control type I error rate. Safety was evaluated in patients who received one or more doses of study drug from week 0 to 56. The study is registered with ClinicalTrials.gov, NCT03090100. Findings This study was done between April 27, 2017, and Sept 20, 2018. 1048 eligible patients were enrolled and, of  these, 534 were assigned to receive guselkumab and 514 to receive secukinumab. The proportion of patients with a  PASI 90 response at week 48 was greater in the guselkumab group (451 [84%]) than in the secukinumab group (360 [70%]; p<0·0001). Although non-inferiority (margin of 10 percentage points) was established for the first major secondary endpoint (452 [85%] of patients in the guselkumab group vs 412 [80%] of patients in the secukinumab group achieving a PASI 75 response at both weeks 12 and 48), superiority was not established (p=0·0616).  Consequently, formal statistical testing was not done for subsequent major secondary endpoints. Proportions of patients with adverse events, infections, and serious adverse events were similar between the two treatments and, in general, safety findings were consistent with registrational trial observations. Interpretation Guselkumab showed superior long-term efficacy based on PASI 90 at week 48 when compared with  secukinumab for treating moderate-to-severe psoriasis. This finding could assist health-care providers in their  decision making process when selecting a biologic for treating moderate-to-severe psoriasis. Funding This study was funded by Janssen Research & Development. Copyright © 2019 Elsevier Ltd. All rights reserved. Introduction Psoriasis, a chronic, systemic inflammatory disease  with prominent skin involvement, affects approximate  ly  2–4% of the world’s population1,2 and profoundly  impairs patients’ health-related quality of life.3–5 Over  the past 15 years, substantial improvements in the efficacy of biologics to treat moderate-to-severe psoriasis have been achieved. 6 As a result, at least a 90% reduc - tion of the baseline Psoriasis Area and Severity Index (PASI 90 response) is replacing PASI 75 as the standard response for measuring successful treatment of psoriasis. 7–9 Multiple psoriasis comparator studies have been done  to evaluate relative efficacy among biologic therapies. These trials have shown superior efficacy for interleukin (IL)-23 blockade versus a tumour necrosis factor (TNF) inhibitor, 10–12 as well as improved responses for IL-17A  neutralisa  tion13,14 and selective blockade of the p19 subunit  of IL-23 (IL-23p19)15 versus an inhibitor of the p40 subunit  of IL-12 and IL-23 (IL-12/23p40). Of note, the primary Published Online  August 8, 2019 http://dx.doi.org/10.1016/ S0140-6736(19)31773-8 See Online/Comment  http://dx.doi.org/10.1016/ S0140-6736(19)31772-6 Institute for Health Services  Research in Dermatology and Nursing, Univ ersity Medical  Center Hamburg-Eppendorf, Hamburg, Germany   (Prof K R eich MD);  Skinflammation Center, Hamburg, Germany (Prof K Reich); University of Southern California, Los Angeles, CA, USA (Prof A W Armstrong MD); Dalhousie University, Halifax, NS, Canada (Prof R G Langley MD); Janssen Research & Development LLC, Spring House, PA, USA (S Flavin PhD, B Randazzo MD, S Li PhD, M-C Hsu PhD, P Branigan BS); and Oregon Medical Research Center, Portland, OR, USA (A Blauvelt MD) Correspondence to:   Prof Kristian Reich, Institute for  Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany   k.reich@uk e.de\n"
     ]
    }
   ],
   "source": [
    "text = page.extract_text()\n",
    "# Replace '\\n' that is not followed by a whitespace or another '\\n'\n",
    "cleaned_text = re.sub(r'\\n(?!\\s|\\n)', ' ', text)\n",
    "print(cleaned_text)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 46,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['Articleswww.thelancet.com   Published online August 8, 2019   http://dx.doi.org/10.1016/S0140-6736(19)31773-8  1Guselkumab versus secukinumab for the treatment of  moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial Kristian Reich, April W Armstrong, Richard G Langley, Susan Flavin, Bruce Randazzo, Shu Li, Ming-Chun Hsu, Patrick Branigan, Andrew Blauvelt Summary Background Antibodies targeting interleukin (IL)-23 and IL-17A effectively treat moderate-to-severe psoriasis',\n",
       " ' ECLIPSE is the first comparator study of an IL-23p19 inhibitor, guselkumab, versus an IL-17A inhibitor, secukinumab',\n",
       " 'The primary objective of this study was to show superiority of clinical response at week 48 for guselkumab versus secukinumab',\n",
       " 'Methods In this phase 3, multicentre, double-blind, randomised, comparator-controlled trial at 142 outpatient  clinical sites in nine countries (Australia, Canada, Czech Republic, France, Germany, Hungary, Poland, Spain, and  the USA), eligible patients were aged 18 years or older, had moderate-to-severe plaque-type psoriasis, and were candidates for phototherapy or systemic therapy',\n",
       " 'Eligible patients were randomly assigned with permuted block randomisation using an interactive web response system to receive either guselkumab (100 mg at weeks 0 and 4 then every 8 weeks) or secukinumab (300 mg at weeks 0, 1, 2, 3, and 4, and then every 4 weeks)',\n",
       " 'The primary endpoint, the proportion of patients in the intention-to-treat population who achieved 90% reduction or more from baseline of Psoriasis Area and Severity Index (PASI 90 response) at week 48, and major secondary endpoints (the proportions of patients in the guselkumab group and in the secukinumab group who achieved a PASI 75 response at both weeks 12 and 48, a PASI 90 response at week 12, a PASI 75 response at week 12, a PASI 100 response at week 48, an Investigator’s Global Assessment [IGA] score of 0 [cleared] at week 48, and an IGA score of 0 or 1 [minimal] at week 48) were to be tested in a fixed sequence to control type I error rate',\n",
       " 'Safety was evaluated in patients who received one or more doses of study drug from week 0 to 56',\n",
       " 'The study is registered with ClinicalTrials.gov, NCT03090100',\n",
       " 'Findings This study was done between April 27, 2017, and Sept 20, 2018',\n",
       " '1048 eligible patients were enrolled and, of  these, 534 were assigned to receive guselkumab and 514 to receive secukinumab',\n",
       " 'The proportion of patients with a  PASI 90 response at week 48 was greater in the guselkumab group (451 [84%]) than in the secukinumab group (360 [70%]; p<0·0001)',\n",
       " 'Although non-inferiority (margin of 10 percentage points) was established for the first major secondary endpoint (452 [85%] of patients in the guselkumab group vs 412 [80%] of patients in the secukinumab group achieving a PASI 75 response at both weeks 12 and 48), superiority was not established (p=0·0616)',\n",
       " ' Consequently, formal statistical testing was not done for subsequent major secondary endpoints',\n",
       " 'Proportions of patients with adverse events, infections, and serious adverse events were similar between the two treatments and, in general, safety findings were consistent with registrational trial observations',\n",
       " 'Interpretation Guselkumab showed superior long-term efficacy based on PASI 90 at week 48 when compared with  secukinumab for treating moderate-to-severe psoriasis',\n",
       " 'This finding could assist health-care providers in their  decision making process when selecting a biologic for treating moderate-to-severe psoriasis',\n",
       " 'Funding This study was funded by Janssen Research & Development',\n",
       " 'Copyright © 2019 Elsevier Ltd',\n",
       " 'All rights reserved',\n",
       " 'Introduction Psoriasis, a chronic, systemic inflammatory disease  with prominent skin involvement, affects approximate  ly  2–4% of the world’s population1,2 and profoundly  impairs patients’ health-related quality of life.3–5 Over  the past 15 years, substantial improvements in the efficacy of biologics to treat moderate-to-severe psoriasis have been achieved',\n",
       " '6 As a result, at least a 90% reduc - tion of the baseline Psoriasis Area and Severity Index (PASI 90 response) is replacing PASI 75 as the standard response for measuring successful treatment of psoriasis',\n",
       " '7–9 Multiple psoriasis comparator studies have been done  to evaluate relative efficacy among biologic therapies',\n",
       " 'These trials have shown superior efficacy for interleukin (IL)-23 blockade versus a tumour necrosis factor (TNF) inhibitor, 10–12 as well as improved responses for IL-17A  neutralisa  tion13,14 and selective blockade of the p19 subunit  of IL-23 (IL-23p19)15 versus an inhibitor of the p40 subunit  of IL-12 and IL-23 (IL-12/23p40)',\n",
       " 'Of note, the primary Published Online  August 8, 2019 http://dx.doi.org/10.1016/ S0140-6736(19)31773-8 See Online/Comment  http://dx.doi.org/10.1016/ S0140-6736(19)31772-6 Institute for Health Services  Research in Dermatology and Nursing, Univ ersity Medical  Center Hamburg-Eppendorf, Hamburg, Germany   (Prof K R eich MD);  Skinflammation Center, Hamburg, Germany (Prof K Reich); University of Southern California, Los Angeles, CA, USA (Prof A W Armstrong MD); Dalhousie University, Halifax, NS, Canada (Prof R G Langley MD); Janssen Research & Development LLC, Spring House, PA, USA (S Flavin PhD, B Randazzo MD, S Li PhD, M-C Hsu PhD, P Branigan BS); and Oregon Medical Research Center, Portland, OR, USA (A Blauvelt MD) Correspondence to:   Prof Kristian Reich, Institute for  Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany   k.reich@uk e.de']"
      ]
     },
     "execution_count": 46,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "corpus = cleaned_text.split('. ')\n",
    "corpus"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "> Note: This is a work in progress. PDF parsing is not the best at this point. \n",
    "\n",
    "- Bad parsing: approximate  ly \n",
    "- not being able to read pdf in sections (just pages) is a bit of a problem.\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 96,
   "metadata": {},
   "outputs": [],
   "source": [
    "len(reader.pages)\n",
    "corpus_all = []\n",
    "corpus_pages = []\n",
    "for page_number in range(len(reader.pages)):\n",
    "    text = reader.pages[page_number].extract_text()\n",
    "    # Replace '\\n' that is not followed by a whitespace or another '\\n'\n",
    "    cleaned_text = re.sub(r'\\n(?!\\s|\\n)', ' ', text)\n",
    "    cleaned_text = cleaned_text.strip()\n",
    "    corpus = cleaned_text.split('. ')\n",
    "    for i in range(len(corpus)):\n",
    "        corpus[i] = corpus[i].strip()\n",
    "    corpus_all.extend(corpus)\n",
    "    corpus_pages.extend([(page_number+1)] * len(corpus))  \n",
    "\n",
    "assert len(corpus_all) == len(corpus_pages)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 99,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\n",
      "======================\n",
      "\n",
      "\n",
      "Query: The primary endpoint was the proportion of patients in each group who achieved a PASI 90 response at week 48.\n",
      "\n",
      "Top 5 most similar sentences in corpus:\n",
      "Page #4:  Articles4 www.thelancet.com   Published online August 8, 2019   http://dx.doi.org/10.1016/S0140-6736(19)31773-8Outcomes The primary endpoint was the proportion of patients in  each group who achieved a PASI 90 response at week 48 (Score: 0.9394)\n",
      "Page #4:  Major secondary endpoints were the proportions of  patients in each group who achieved a PASI 75 response at both week 12 and week 48, a PASI 90 response at week 12, a PASI 75 response at week 12, a PASI 100 response at week 48, an IGA score of 0 (cleared) at week 48, and an IGA score of 0 (cleared) or 1 (minimal) at week 48 (Score: 0.8571)\n",
      "Page #4:  Other secondary endpoints were the proportion of patients achieving a PASI 90 response, a PASI 100 response, an IGA score of 0 (cleared), and an IGA score of 0 (cleared) or 1 (minimal) over time until week 48 (Score: 0.8431)\n",
      "Page #2:  The primary endpoint of the study was based on PASI 90 response at week 48, to focus on longer-term response in this chronic disease (Score: 0.7906)\n",
      "Page #6:  Endpoints assessed at week 12 included the proportions  of patients achieving a PASI 90 response (369 [69%] of 534 patients in the guselkumab group vs 391 [76%] of 514 patients in the secukinumab group) and a PASI 75 response (477 [89%] vs 471 [92%]; table 2) (Score: 0.7755)\n",
      "\n",
      "\n",
      "======================\n",
      "\n",
      "\n",
      "Query: HEAD-TO-HEAD RESULTS: TREMFYA® 48-WEEK EFFICACY DATA VS. COSENTYX\n",
      "\n",
      "Top 5 most similar sentences in corpus:\n",
      "Page #2:  This report also provides a comprehensive assessment of efficacy over time in which clear differences were observed (Score: 0.5874)\n",
      "Page #3:  Efficacy and safety were assessed throughout weeks 0–56;  during weeks 44–56 patients were followed up at weeks 48 and 56 (Score: 0.5514)\n",
      "Page #6:  As prespecified, the percentage improvement from  baseline in PASI was assessed by study visit and treatment group.The time to achieve a median PASI improvement from baseline of 50% was 2·7 weeks (95% CI 2·6–2·9) for guselkumab versus 2·3 weeks (2·2–2·4) for secukinumab, and 8·2 weeks (7·8–9·1) versus 7·4 weeks (7·0–7·5) for a median PASI improvement of 90% (figure 3) (Score: 0.5146)\n",
      "Page #2:  The proportions of patients with a response for other stringent longer-term efficacy endpoints (PASI 100, Investigator’s Global Assessment [IGA] score of 0, and IGA score of 0 or 1 at week 48) were also numerically higher for guselkumab than for secukinumab, although formal statistical testing was not done (Score: 0.5061)\n",
      "Page #3:  During the treatment period, patients received either guselkumab 100 mg (TREMFYA; Janssen Research & Development, Spring House, PA, USA) by sub\n",
      " cutaneous  injection at weeks 0, 4, 12, and every 8 weeks thereafter until week 44, or secukinumab 300 mg (COSENTYX; Novartis Pharmaceuticals Corporation, East Hanover , NJ,  USA) administered as two 150-mg subcutaneous injections at weeks 0, 1, 2, 3, and 4, and every 4 weeks thereafter until week 44 (figure 1A) (Score: 0.5033)\n",
      "\n",
      "\n",
      "======================\n",
      "\n",
      "\n",
      "Query: TREMFYA® demonstrated a superior PASI 90 response vs. COSENTYX at Week 48 (ITT population)\n",
      "\n",
      "Top 5 most similar sentences in corpus:\n",
      "Page #4:  Articles4 www.thelancet.com   Published online August 8, 2019   http://dx.doi.org/10.1016/S0140-6736(19)31773-8Outcomes The primary endpoint was the proportion of patients in  each group who achieved a PASI 90 response at week 48 (Score: 0.6317)\n",
      "Page #1:  The proportion of patients with a  PASI 90 response at week 48 was greater in the guselkumab group (451 [84%]) than in the secukinumab group (360 [70%]; p<0·0001) (Score: 0.6139)\n",
      "Page #7:  The proportion of patients with a PASI 90 response peaked at week 20 and then declined in the secukinumab group, whereas the proportion of patients with a PASI 90 response peaked later (week 28) and remained stable until week 48 in the guselkumab group (Score: 0.6056)\n",
      "Page #2:  The primary endpoint of the study was based on PASI 90 response at week 48, to focus on longer-term response in this chronic disease (Score: 0.5917)\n",
      "Page #2:  Between week 3 and week 12, the proportions of patients achieving a PASI 90 response were higher in the secukinumab group than in the guselkumab group; at weeks 16 and 20 they were similar in the two groups; and from week 28 to 48 they were higher in the guselkumab group (Score: 0.5833)\n",
      "\n",
      "\n",
      "======================\n",
      "\n",
      "\n",
      "Query: Patients were ≥18 years with moderate-to-severe plaque psoriasis (PASI ≥12, Investigator’s Global Assessment  score ≥3, body surface area involvement ≥10% for ≥6 months) and were candidates for phototherapy or systemic therapy. Patients received either TREMFYA® 100 mg subcutaneously (SC) at Weeks 0, 4, 12, and every 8 weeks thereafter until Week 44 or COSENTYX 300 mg administered as two SC injections at Weeks 0, 1, 2, 3, and 4, and every 4 weeks thereafter until Week 44. Primary endpoint was the proportion of patients in each group who achieved a PASI 90 response at Week 48\n",
      "\n",
      "Top 5 most similar sentences in corpus:\n",
      "Page #3:  Articleswww.thelancet.com   Published online August 8, 2019   http://dx.doi.org/10.1016/S0140-6736(19)31773-8  3Eligible patients (aged ≥18 years) had moderate-to- severe plaque-type psoriasis (PASI ≥12, Investigator’s  Global Assessment [IGA] score ≥3, body surface area involvement ≥10% for ≥6 months) and were candidates for phototherapy or systemic therapy (Score: 0.8323)\n",
      "Page #1:  Methods In this phase 3, multicentre, double-blind, randomised, comparator-controlled trial at 142 outpatient  clinical sites in nine countries (Australia, Canada, Czech Republic, France, Germany, Hungary, Poland, Spain, and  the USA), eligible patients were aged 18 years or older, had moderate-to-severe plaque-type psoriasis, and were candidates for phototherapy or systemic therapy (Score: 0.8063)\n",
      "Page #1:  6 As a result, at least a 90% reduc - tion of the baseline Psoriasis Area and Severity Index (PASI 90 response) is replacing PASI 75 as the standard response for measuring successful treatment of psoriasis (Score: 0.6897)\n",
      "Page #2:  We observed from this search that although significant improvements in the efficacy of biologics for the treatment of moderate-to-severe psoriasis have been made, patients’ desire for clear skin, and stable, long-term control is generally of greater relevance than an early response (Score: 0.6660)\n",
      "Page #1:  7–9 Multiple psoriasis comparator studies have been done  to evaluate relative efficacy among biologic therapies (Score: 0.6616)\n"
     ]
    }
   ],
   "source": [
    "eclispse_claims = [\n",
    "    'The primary endpoint was the proportion of patients in each group who achieved a PASI 90 response at week 48.',\n",
    "    'HEAD-TO-HEAD RESULTS: TREMFYA® 48-WEEK EFFICACY DATA VS. COSENTYX',\n",
    "    'TREMFYA® demonstrated a superior PASI 90 response vs. COSENTYX at Week 48 (ITT population)',\n",
    "    'Patients were ≥18 years with moderate-to-severe plaque psoriasis (PASI ≥12, Investigator’s Global Assessment  score ≥3, body surface area involvement ≥10% for ≥6 months) and were candidates for phototherapy or systemic therapy. Patients received either TREMFYA® 100 mg subcutaneously (SC) at Weeks 0, 4, 12, and every 8 weeks thereafter until Week 44 or COSENTYX 300 mg administered as two SC injections at Weeks 0, 1, 2, 3, and 4, and every 4 weeks thereafter until Week 44. Primary endpoint was the proportion of patients in each group who achieved a PASI 90 response at Week 48']\n",
    "\n",
    "\n",
    "embedder = SentenceTransformer(\"all-MiniLM-L6-v2\")\n",
    "\n",
    "corpus_embeddings = embedder.encode(corpus_all, convert_to_tensor=True)\n",
    "\n",
    "\n",
    "# Find the closest 5 sentences of the corpus for each query sentence based on cosine similarity\n",
    "top_k = min(5, len(corpus_all))\n",
    "for query in eclispse_claims:\n",
    "    query_embedding = embedder.encode(query, convert_to_tensor=True)\n",
    "\n",
    "    # We use cosine-similarity and torch.topk to find the highest 5 scores\n",
    "    cos_scores = util.cos_sim(query_embedding, corpus_embeddings)[0]\n",
    "    top_results = torch.topk(cos_scores, k=top_k)\n",
    "\n",
    "    print(\"\\n\\n======================\\n\\n\")\n",
    "    print(\"Query:\", query)\n",
    "    print(\"\\nTop 5 most similar sentences in corpus:\")\n",
    "\n",
    "    for score, idx in zip(top_results[0], top_results[1]):\n",
    "        print(f\"Page #{corpus_pages[idx]}: \",corpus_all[idx], \"(Score: {:.4f})\".format(score))\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# New approach using langchain"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "from PyPDF2 import PdfReader\n",
    "from pdfplumber import pdf\n",
    "from langchain.text_splitter import RecursiveCharacterTextSplitter\n",
    "from sentence_transformers import SentenceTransformer, util\n",
    "import time\n",
    "from gpt4all import GPT4All\n",
    "\n",
    "from numba import jit, cuda\n",
    "import numpy as np  \n",
    "\n",
    "\n",
    "import sys,time,random\n",
    "\n",
    "def progressBar(count_value, total, suffix=''):\n",
    "    bar_length = 100\n",
    "    filled_up_Length = int(round(bar_length* count_value / float(total)))\n",
    "    percentage = round(100.0 * count_value/float(total),1)\n",
    "    bar = '=' * filled_up_Length + '-' * (bar_length - filled_up_Length)\n",
    "    sys.stdout.write('[%s] %s%s ...%s\\r' %(bar, percentage, '%', suffix))\n",
    "    sys.stdout.flush()\n",
    "\n",
    "# Loading the llm model here\n",
    "llm = GPT4All(\"orca-mini-3b.ggmlv3.q4_0.bin\")\n",
    "\n",
    "def get_query():\n",
    "    query = input(\"Enter your question\\n\")\n",
    "    progressBar(1, 7)\n",
    "    return query\n",
    "\n",
    "\n",
    "def load_split_pdf(pdf_path):\n",
    "    pdf_loader = PdfReader(open(pdf_path, \"rb\"))\n",
    "    pdf_text = \"\"\n",
    "    for page_num in range(len(pdf_loader.pages)):\n",
    "        pdf_page = pdf_loader.pages[page_num]\n",
    "        pdf_text += pdf_page.extract_text()\n",
    "    progressBar(2, 7)\n",
    "    return pdf_text\n",
    "\n",
    "\n",
    "def split_text_using_RCTS(pdf_text):\n",
    "    text_splitter = RecursiveCharacterTextSplitter(\n",
    "    chunk_size=2048,\n",
    "    chunk_overlap=64\n",
    "    )\n",
    "    split_texts = text_splitter.split_text(pdf_text)\n",
    "    paragraphs = []\n",
    "    for text in split_texts:\n",
    "        paragraphs.extend(text.split('\\n')) \n",
    "    progressBar(3, 7)\n",
    "    return paragraphs\n",
    "\n",
    "\n",
    "def Initialize_sentence_transformer():\n",
    "    model_name = \"sentence-transformers/all-MiniLM-L6-v2\"\n",
    "    embeddings = SentenceTransformer(model_name)\n",
    "    progressBar(4, 7)\n",
    "    return embeddings\n",
    "\n",
    "\n",
    "def encode_each_paragraph(paragraphs, embeddings):\n",
    "    responses = []\n",
    "    for paragraph in paragraphs:\n",
    "        response = embeddings.encode([paragraph], convert_to_tensor=True)\n",
    "        responses.append((paragraph, response))\n",
    "    progressBar(5, 7)\n",
    "    return responses\n",
    "\n",
    "\n",
    "def choose_most_relevant_sentence(embeddings, responses, query):\n",
    "    query_embedding = embeddings.encode([query], convert_to_tensor=True)\n",
    "    best_response = None\n",
    "    best_similarity = -1.0\n",
    "    answers = []\n",
    "\n",
    "    for paragraph, response in responses:\n",
    "        \n",
    "        similarity = util.pytorch_cos_sim(query_embedding, response).item()\n",
    "        \n",
    "        if similarity >= 0.6:\n",
    "            \n",
    "            # count += 1\n",
    "            \n",
    "            answers.append(paragraph)\n",
    "    answer = \"\\n\".join(answers)\n",
    "    progressBar(6, 7)\n",
    "    return answer\n",
    "\n",
    "\n",
    "def query_the_llm(answer, llm_model, query):\n",
    "    prompt_message = answer + \"\\n\" + query\n",
    "\n",
    "    final_response = llm_model.generate(prompt=prompt_message)\n",
    "    \n",
    "    return final_response\n",
    "\n",
    "    \n",
    "\n",
    "def main(llm):\n",
    "    start_time = time.time()\n",
    "    \n",
    "    pdf_path = \"\"\n",
    "    \n",
    "    query = get_query()\n",
    "    \n",
    "    pdf_text = load_split_pdf(pdf_path)\n",
    "    \n",
    "    paragraphs = split_text_using_RCTS(pdf_text)\n",
    "    \n",
    "    embeddings = Initialize_sentence_transformer()\n",
    "    \n",
    "    responses = encode_each_paragraph(paragraphs=paragraphs, embeddings=embeddings)\n",
    "    \n",
    "    answer = choose_most_relevant_sentence(embeddings=embeddings, responses=responses, query=query)\n",
    "    \n",
    "    final_response = query_the_llm(answer=answer, llm_model=llm, query=query)\n",
    "    \n",
    "    print (\"The answer from model is\\n\", final_response)\n",
    "    \n",
    "    end_time = time.time()\n",
    "    elapsed_time = end_time - start_time\n",
    "    \n",
    "    print(f\"Execution time: {elapsed_time/60} minutes \\n\")\n",
    "    \n",
    "    progressBar(7, 7)\n",
    "\n",
    "main(llm)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "from PyPDF2 import PdfReader\n",
    "from pdfplumber import pdf\n",
    "from langchain.text_splitter import RecursiveCharacterTextSplitter\n",
    "from sentence_transformers import SentenceTransformer, util\n",
    "import time\n",
    "# from gpt4all import GPT4All\n",
    "\n",
    "# from numba import jit, cuda\n",
    "import numpy as np  \n",
    "\n",
    "\n",
    "import sys,time,random\n",
    "\n",
    "def progressBar(count_value, total, suffix=''):\n",
    "    bar_length = 100\n",
    "    filled_up_Length = int(round(bar_length* count_value / float(total)))\n",
    "    percentage = round(100.0 * count_value/float(total),1)\n",
    "    bar = '=' * filled_up_Length + '-' * (bar_length - filled_up_Length)\n",
    "    sys.stdout.write('[%s] %s%s ...%s\\r' %(bar, percentage, '%', suffix))\n",
    "    sys.stdout.flush()\n",
    "\n",
    "# Loading the llm model here\n",
    "# llm = GPT4All(\"orca-mini-3b.ggmlv3.q4_0.bin\")\n",
    "\n",
    "def get_query():\n",
    "    query = input(\"Enter your question\\n\")\n",
    "    progressBar(1, 7)\n",
    "    return query\n",
    "\n",
    "\n",
    "def load_split_pdf(pdf_path):\n",
    "    pdf_loader = PdfReader(open(pdf_path, \"rb\"))\n",
    "    pdf_text = \"\"\n",
    "    for page_num in range(len(pdf_loader.pages)):\n",
    "        pdf_page = pdf_loader.pages[page_num]\n",
    "        pdf_text += pdf_page.extract_text()\n",
    "    progressBar(2, 7)\n",
    "    return pdf_text\n",
    "\n",
    "\n",
    "def split_text_using_RCTS(pdf_text):\n",
    "    text_splitter = RecursiveCharacterTextSplitter(\n",
    "    chunk_size=2048,\n",
    "    chunk_overlap=64\n",
    "    )\n",
    "    split_texts = text_splitter.split_text(pdf_text)\n",
    "    paragraphs = []\n",
    "    for text in split_texts:\n",
    "        paragraphs.extend(text.split('\\n')) \n",
    "    progressBar(3, 7)\n",
    "    return paragraphs\n",
    "\n",
    "\n",
    "def Initialize_sentence_transformer():\n",
    "    model_name = \"sentence-transformers/all-MiniLM-L6-v2\"\n",
    "    embeddings = SentenceTransformer(model_name)\n",
    "    progressBar(4, 7)\n",
    "    return embeddings\n",
    "\n",
    "\n",
    "def encode_each_paragraph(paragraphs, embeddings):\n",
    "    responses = []\n",
    "    for paragraph in paragraphs:\n",
    "        response = embeddings.encode([paragraph], convert_to_tensor=True)\n",
    "        responses.append((paragraph, response))\n",
    "    progressBar(5, 7)\n",
    "    return responses\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "pdf_path = \"\"\n",
    "query = get_query()\n",
    "pdf_text = load_split_pdf(pdf_path)\n",
    "paragraphs = split_text_using_RCTS(pdf_text)\n",
    "embeddings = Initialize_sentence_transformer()\n",
    "responses = encode_each_paragraph(paragraphs=paragraphs, embeddings=embeddings)\n",
    "answer = choose_most_relevant_sentence(embeddings=embeddings, responses=responses, query=query)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Spacy pdf reader"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1\n",
      "47\n",
      "data\\MASTER_TremfyaPM_08Nov2022.pdf\n",
      "(1, 47)\n",
      "1\n",
      "47\n",
      "PART I: HEALTH PROFESSIONAL INFORMATION\n",
      "\n",
      "1\n",
      "\n",
      "INDICATIONS\n",
      "\n",
      "Plaque Psoriasis\n",
      "\n",
      "Psoriatic Arthritis\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "1.1 Pediatrics\n",
      "\n",
      "1.2 Geriatrics\n",
      "\n",
      "TREMFYA®/TREMFYA One-Press® (guselkumab injection) is indicated for:\n",
      "\n",
      "the treatment of adult patients with moderate-to-severe plaque psoriasis who are \n",
      "candidates for systemic therapy or phototherapy. \n",
      "\n",
      "TREMFYA®/TREMFYA One-Press® (guselkumab injection) is indicated for: \n",
      "\n",
      "the treatment of adult patients with active psoriatic arthritis. TREMFYA®/TREMFYA One-\n",
      "Press® can be used alone or in combination with a conventional disease-modifying \n",
      "antirheumatic drug (cDMARD) (e.g., methotrexate).\n",
      "\n",
      "The safety and efficacy of TREMFYA®/TREMFYA One-Press® in pediatric patients have not \n",
      "been evaluated.\n",
      "\n",
      "Of the 3406 plaque psoriasis and psoriatic arthritis patients exposed to TREMFYA®/TREMFYA \n",
      "One-Press® in Phase 2 and Phase 3 clinical trials, a limited number of patients were 65 years or \n",
      "older (n = 185, 5%) or 75 years and older (n=13, 0.4%). Thus, data in these age groups are \n",
      "limited (see 10 CLINICAL PHARMACOLOGY).\n",
      "\n",
      "2 CONTRAINDICATIONS\n",
      "\n",
      "TREMFYA®/TREMFYA One-Press® is contraindicated in patients with known serious \n",
      "hypersensitivity to guselkumab or any of the components. For a complete listing of components, \n",
      "see the 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING section.\n",
      "\n",
      "4 DOSAGE AND ADMINISTRATION\n",
      "\n",
      "TREMFYA®/TREMFYA One-Press® is administered by subcutaneous injection.\n",
      "\n",
      "4.1 Dosing Considerations\n",
      "\n",
      "TREMFYA®/TREMFYA One-Press® is intended for use under the guidance and supervision of a \n",
      "physician. \n",
      "\n",
      "TREMFYA®/TREMFYA One-Press® may be administered by a healthcare professional, or a \n",
      "patient or caregiver may administer the injection after proper training in subcutaneous injection \n",
      "technique. \n",
      "\n",
      "4.2 Recommended Dose and Dosage Adjustment\n",
      "\n",
      "Plaque psoriasis\n",
      "The recommended dose of TREMFYA®/TREMFYA One-Press® is 100 mg to be given as \n",
      "\n",
      "TRE11082022CPM_SNDS 259046.docx\n",
      "EDMS-ERI-121169578 v15.0\n",
      "\n",
      "Page 4 of 47\n",
      "\n",
      "\f\n"
     ]
    },
    {
     "ename": "AttributeError",
     "evalue": "[E046] Can't retrieve unregistered extension attribute 'page_paragraphs'. Did you forget to call the `set_extension` method?",
     "output_type": "error",
     "traceback": [
      "\u001b[1;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[1;31mAttributeError\u001b[0m                            Traceback (most recent call last)",
      "Cell \u001b[1;32mIn[6], line 22\u001b[0m\n\u001b[0;32m     19\u001b[0m \u001b[38;5;28mprint\u001b[39m(doc\u001b[38;5;241m.\u001b[39m_\u001b[38;5;241m.\u001b[39mpage(\u001b[38;5;241m4\u001b[39m))         \u001b[38;5;66;03m# 'able to display the destination page (unless...'\u001b[39;00m\n\u001b[0;32m     21\u001b[0m \u001b[38;5;66;03m# Get all of the text from a specific PDF page. and transform into paragraphs\u001b[39;00m\n\u001b[1;32m---> 22\u001b[0m \u001b[38;5;28mprint\u001b[39m(\u001b[43mdoc\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mpage_paragraphs\u001b[49m(\u001b[38;5;241m4\u001b[39m))\n",
      "File \u001b[1;32mc:\\myFiles\\personal\\Yama\\.env\\lib\\site-packages\\spacy\\tokens\\underscore.py:48\u001b[0m, in \u001b[0;36mUnderscore.__getattr__\u001b[1;34m(self, name)\u001b[0m\n\u001b[0;32m     46\u001b[0m \u001b[38;5;28;01mdef\u001b[39;00m \u001b[38;5;21m__getattr__\u001b[39m(\u001b[38;5;28mself\u001b[39m, name: \u001b[38;5;28mstr\u001b[39m) \u001b[38;5;241m-\u001b[39m\u001b[38;5;241m>\u001b[39m Any:\n\u001b[0;32m     47\u001b[0m     \u001b[38;5;28;01mif\u001b[39;00m name \u001b[38;5;129;01mnot\u001b[39;00m \u001b[38;5;129;01min\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_extensions:\n\u001b[1;32m---> 48\u001b[0m         \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;167;01mAttributeError\u001b[39;00m(Errors\u001b[38;5;241m.\u001b[39mE046\u001b[38;5;241m.\u001b[39mformat(name\u001b[38;5;241m=\u001b[39mname))\n\u001b[0;32m     49\u001b[0m     default, method, getter, setter \u001b[38;5;241m=\u001b[39m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_extensions[name]\n\u001b[0;32m     50\u001b[0m     \u001b[38;5;28;01mif\u001b[39;00m getter \u001b[38;5;129;01mis\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m \u001b[38;5;28;01mNone\u001b[39;00m:\n",
      "\u001b[1;31mAttributeError\u001b[0m: [E046] Can't retrieve unregistered extension attribute 'page_paragraphs'. Did you forget to call the `set_extension` method?"
     ]
    }
   ],
   "source": [
    "import spacy\n",
    "from spacypdfreader.spacypdfreader import pdf_reader\n",
    "pdf_path = 'data/MASTER_TremfyaPM_08Nov2022.pdf'\n",
    "\n",
    "nlp = spacy.load('en_core_web_sm')\n",
    "doc = pdf_reader(pdf_path, nlp)\n",
    "\n",
    "# Get the page number of any token.\n",
    "print(doc[0]._.page_number)  # 1\n",
    "print(doc[-1]._.page_number) # 4\n",
    "\n",
    "# Get page meta data about the PDF document.\n",
    "print(doc._.pdf_file_name)   # 'tests/data/test_pdf_01.pdf'\n",
    "print(doc._.page_range)      # (1, 4)\n",
    "print(doc._.first_page)      # 1\n",
    "print(doc._.last_page)       # 4\n",
    "\n",
    "# Get all of the text from a specific PDF page.\n",
    "print(doc._.page(4))         # 'able to display the destination page (unless...'\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'PRODUCT MONOGRAPH\\n\\nINCLUDING PATIENT MEDICATION INFORMATION\\n\\nPrTREMFYA®\\nguselkumab injection\\nSolution for injection, \\n100 mg/1 mL\\nPre-filled syringe\\n\\nPrTREMFYA One-Press®\\nguselkumab injection\\nSolution for injection, \\n100 mg/1 mL \\nPatient-controlled injector\\nInterleukin-23 (IL-23) inhibitor\\n\\nTREMFYA®/TREMFYA One-Press® (guselkumab injection) should be prescribed by physicians \\nwho have sufficient knowledge of plaque psoriasis or psoriatic arthritis and who have fully \\nfamiliarized themselves with the efficacy/safety profile of the drug.\\n\\nJanssen Inc.\\n19 Green Belt Drive\\nToronto, Ontario\\nM3C 1L9\\n\\nwww.janssen.com/canada\\n\\nSubmission Control Number: 259046\\n\\nAll trademarks used under license\\n\\n© 2022 JANSSEN Inc.\\n\\nTRE11082022CPM_SNDS 259046.docx\\nEDMS-ERI-121169578 v15.0\\n\\nDate of Initial Authorization:\\nNovember 10, 2017\\n\\nDate of Revision:\\nNovember 08, 2022\\n\\nPage 1 of 47\\n\\n\\x0cRECENT MAJOR LABEL CHANGES\\n\\n1 Indications\\n4 Dosage and Administration, 4.2 Recommended Dose and Dosage Adjustment\\n7 Warnings and Precautions\\n\\n09/2020\\n09/2020\\n09/2020\\n\\nTABLE OF CONTENTS\\n\\nSections or subsections that are not applicable at the time of authorization are not listed.\\n\\nRECENT MAJOR LABEL CHANGES ........................................................................................2\\n\\nTABLE OF CONTENTS .............................................................................................................2\\n\\nPART I: HEALTH PROFESSIONAL INFORMATION.................................................................4\\n\\n1\\n\\n2\\n\\n4\\n\\n5\\n\\n6\\n\\n7\\n\\nINDICATIONS .................................................................................................................4\\n\\n1.1 Pediatrics...............................................................................................................4\\n\\n1.2 Geriatrics ...............................................................................................................4\\n\\nCONTRAINDICATIONS ..................................................................................................4\\n\\nDOSAGE AND ADMINISTRATION ................................................................................4\\n\\n4.1 Dosing Considerations...........................................................................................4\\n\\n4.2 Recommended Dose and Dosage Adjustment.......................................................4\\n\\n4.4 Administration ........................................................................................................5\\n\\n4.5 Missed Dose ..........................................................................................................6\\n\\nOVERDOSAGE...............................................................................................................6\\n\\nDOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING .........................6\\n\\nWARNINGS AND PRECAUTIONS .................................................................................7\\n\\n7.1 Special Populations ...............................................................................................8\\n\\n7.1.1\\n\\nPregnant Women .............................................................................................. 8\\n\\n7.1.2\\n\\nBreast-feeding................................................................................................... 8\\n\\n7.1.3\\n\\nPediatrics .......................................................................................................... 9\\n\\n7.1.4 Geriatrics........................................................................................................... 9\\n\\n8\\n\\nADVERSE REACTIONS .................................................................................................9\\n\\n8.1 Adverse Reaction Overview...................................................................................9\\n\\n8.2 Clinical Trial Adverse Reactions.............................................................................9\\n\\n8.3\\n\\nLess Common Clinical Trial Adverse Reactions...................................................13\\n\\n8.5 Post-Market Adverse Reactions...........................................................................13\\n\\n9\\n\\nDRUG INTERACTIONS ................................................................................................14\\n\\n9.4 Drug-Drug Interactions.........................................................................................14\\n\\nTRE11082022CPM_SNDS 259046.docx\\nEDMS-ERI-121169578 v15.0\\n\\nPage 2 of 47\\n\\n\\x0c9.5 Drug-Food Interactions ........................................................................................14\\n\\n9.6 Drug-Herb Interactions.........................................................................................14\\n\\n9.7 Drug-Laboratory Test Interactions........................................................................14\\n\\n10\\n\\nCLINICAL PHARMACOLOGY......................................................................................14\\n\\n10.1\\n\\n10.2\\n\\n10.3\\n\\nMechanism of Action ........................................................................................14\\n\\nPharmacodynamics..........................................................................................15\\n\\nPharmacokinetics .............................................................................................15\\n\\nSTORAGE, STABILITY AND DISPOSAL.....................................................................16\\n\\nSPECIAL HANDLING INSTRUCTIONS........................................................................16\\n\\nPART II: SCIENTIFIC INFORMATION .....................................................................................17\\n\\nPHARMACEUTICAL INFORMATION...........................................................................17\\n\\nCLINICAL TRIALS........................................................................................................17\\n\\n14.1\\n\\nClinical Trials by Indication ...............................................................................17\\n\\nPlaque Psoriasis............................................................................................................17\\n\\nPsoriatic Arthritis ...........................................................................................................21\\n\\n16\\n\\nNON-CLINICAL TOXICOLOGY ....................................................................................25\\n\\nPATIENT MEDICATION INFORMATION .................................................................................27\\n\\nINSTRUCTIONS FOR USE (TREMFYA®) .....................................................................33\\n\\nINSTRUCTIONS FOR USE (TREMFYA One-Press®) ...................................................41\\n\\n11\\n\\n12\\n\\n13\\n\\n14\\n\\nTRE11082022CPM_SNDS 259046.docx\\nEDMS-ERI-121169578 v15.0\\n\\nPage 3 of 47\\n\\n\\x0cPART I: HEALTH PROFESSIONAL INFORMATION\\n\\n1\\n\\nINDICATIONS\\n\\nPlaque Psoriasis\\n\\nPsoriatic Arthritis\\n\\n\\uf0b7\\n\\n\\uf0b7\\n\\n1.1 Pediatrics\\n\\n1.2 Geriatrics\\n\\nTREMFYA®/TREMFYA One-Press® (guselkumab injection) is indicated for:\\n\\nthe treatment of adult patients with moderate-to-severe plaque psoriasis who are \\ncandidates for systemic therapy or phototherapy. \\n\\nTREMFYA®/TREMFYA One-Press® (guselkumab injection) is indicated for: \\n\\nthe treatment of adult patients with active psoriatic arthritis. TREMFYA®/TREMFYA One-\\nPress® can be used alone or in combination with a conventional disease-modifying \\nantirheumatic drug (cDMARD) (e.g., methotrexate).\\n\\nThe safety and efficacy of TREMFYA®/TREMFYA One-Press® in pediatric patients have not \\nbeen evaluated.\\n\\nOf the 3406 plaque psoriasis and psoriatic arthritis patients exposed to TREMFYA®/TREMFYA \\nOne-Press® in Phase 2 and Phase 3 clinical trials, a limited number of patients were 65 years or \\nolder (n = 185, 5%) or 75 years and older (n=13, 0.4%). Thus, data in these age groups are \\nlimited (see 10 CLINICAL PHARMACOLOGY).\\n\\n2 CONTRAINDICATIONS\\n\\nTREMFYA®/TREMFYA One-Press® is contraindicated in patients with known serious \\nhypersensitivity to guselkumab or any of the components. For a complete listing of components, \\nsee the 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING section.\\n\\n4 DOSAGE AND ADMINISTRATION\\n\\nTREMFYA®/TREMFYA One-Press® is administered by subcutaneous injection.\\n\\n4.1 Dosing Considerations\\n\\nTREMFYA®/TREMFYA One-Press® is intended for use under the guidance and supervision of a \\nphysician. \\n\\nTREMFYA®/TREMFYA One-Press® may be administered by a healthcare professional, or a \\npatient or caregiver may administer the injection after proper training in subcutaneous injection \\ntechnique. \\n\\n4.2 Recommended Dose and Dosage Adjustment\\n\\nPlaque psoriasis\\nThe recommended dose of TREMFYA®/TREMFYA One-Press® is 100 mg to be given as \\n\\nTRE11082022CPM_SNDS 259046.docx\\nEDMS-ERI-121169578 v15.0\\n\\nPage 4 of 47\\n\\n\\x0csubcutaneous injection at week 0 and week 4, followed by maintenance dosing every 8 weeks \\nthereafter.\\n\\nPsoriatic arthritis\\nThe recommended dose of TREMFYA®/TREMFYA One-Press® is 100 mg to be given as \\nsubcutaneous injection at week 0 and week 4, followed by maintenance dosing every 8 weeks \\nthereafter.  \\n\\nTREMFYA®/TREMFYA One-Press® can be used alone or in combination with a conventional \\ndisease-modifying antirheumatic drug (cDMARD) (e.g., methotrexate).\\n\\nSpecial populations\\nPediatrics (< 18 years of age)\\nThe safety and efficacy of TREMFYA®/TREMFYA One-Press® in pediatric patients have not \\nbeen evaluated; therefore, no recommendations on dosing can be made. \\n\\nElderly (≥ 65 years of age)\\nOf the 3406 plaque psoriasis and psoriatic arthritis patients exposed to TREMFYA®/TREMFYA \\nOne-Press® in Phase 2 and Phase 3 clinical trials, a limited number of patients were 65 years or \\nolder (n = 185, 5%) or 75 years and older (n=13, 0.4%). Thus, data in these age groups are \\nlimited (see 10 CLINICAL PHARMACOLOGY).\\n\\nRenal impairment\\nSpecific studies of TREMFYA®/TREMFYA One-Press® have not been conducted in patients \\nwith renal insufficiency.\\n\\nHepatic impairment\\nSpecific studies of TREMFYA®/TREMFYA One-Press® have not been conducted in patients \\nwith hepatic insufficiency. \\n\\n4.4 Administration\\n\\nTREMFYA®/TREMFYA One-Press® is administered by subcutaneous injection. \\nTREMFYA®/TREMFYA One-Press® is intended for use under the guidance and supervision of a \\nphysician. TREMFYA®/TREMFYA One-Press® may be administered by a healthcare \\nprofessional or a patient or caregiver may administer the injection after proper training in \\nsubcutaneous injection technique. \\n\\nThe full amount of TREMFYA® /TREMFYA One-Press® should be injected according to the \\ndirections provided in the “Instructions for Use” document.  \\n\\nBefore injection, remove TREMFYA®/TREMFYA One-Press® from the refrigerator and allow \\nTREMFYA®/TREMFYA One-Press® to reach room temperature (30 minutes) without removing \\nthe needle cap.\\n\\nInspect TREMFYA®/TREMFYA One-Press® visually for particulate matter and discoloration prior \\nto administration. TREMFYA®/TREMFYA One-Press® is a clear and colourless to light yellow \\nsolution. Do not use if the liquid contains large particles, is discoloured or cloudy. Discard any \\n\\nTRE11082022CPM_SNDS 259046.docx\\nEDMS-ERI-121169578 v15.0\\n\\nPage 5 of 47\\n\\n\\x0cunused product remaining after injection. \\n\\n4.5 Missed Dose\\n\\nPatients who miss a dose of TREMFYA®/TREMFYA One-Press® should be advised to inject this \\nmissed dose as soon as they become aware of it, and then follow with their next scheduled \\ndose.\\n\\n5 OVERDOSAGE\\n\\nSingle intravenous doses of TREMFYA® up to 987 mg (10 mg/kg) have been administered in \\nhealthy volunteers and single subcutaneous doses of TREMFYA® up to 300 mg have been \\nadministered in patients with plaque psoriasis in clinical trials without dose-limiting toxicity. In \\nthe event of overdosage, monitor the patient for any signs or symptoms of adverse reactions \\nand administer appropriate symptomatic treatment immediately.\\n\\nFor management of a suspected drug overdose, contact your regional Poison Control \\nCentre.\\n\\n6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING\\n\\nTo help ensure the traceability of biologic products, including biosimilars, health professionals \\nshould recognize the importance of recording both the brand name and the non-proprietary \\n(active ingredient) name as well as other product-specific identifiers such as the Drug \\nIdentification Number (DIN) and the batch/lot number of the product supplied.\\n\\nRoute of \\nAdministration\\nSubcutaneous \\nInjection (SC)\\n\\nSubcutaneous \\nInjection (SC)\\n\\nDosage Form / \\nStrength\\nSterile solution for \\ninjection in pre-filled \\nsyringe, (100 mg/ 1 mL)\\nSterile solution for \\ninjection in a patient-\\ncontrolled injector, \\n(100 mg/ 1 mL)\\n\\nClinically Relevant Nonmedicinal Ingredients\\n\\nL-histidine, L-histidine monohydrochloride \\nmonohydrate, polysorbate 80, sucrose and water \\nfor injection\\nL-histidine, L-histidine monohydrochloride \\nmonohydrate, polysorbate 80, sucrose and water \\nfor injection\\n\\nTREMFYA®/TREMFYA One-Press® (guselkumab injection) is a fully human immunoglobulin G1 \\nlambda (IgG1λ) monoclonal antibody (mAb) that binds selectively to the extracellular human \\ninterleukin 23 (IL-23) protein with high specificity and affinity. Guselkumab is produced in a \\nmammalian cell line using recombinant DNA technology.\\n\\nTREMFYA® is supplied as:\\n\\nA sterile solution in a single-dose 1mL glass syringe with a 27G, half inch fixed needle \\nassembled in a passive needle guard delivery system, containing 100 mg guselkumab, \\n(100 mg/1 mL in a 1 mL syringe volume) packaged in a carton.\\n\\nTRE11082022CPM_SNDS 259046.docx\\nEDMS-ERI-121169578 v15.0\\n\\nPage 6 of 47\\n\\n\\x0cTREMFYA One-Press® is supplied as: \\n\\nA sterile solution in a single-dose 1mL glass syringe with a 27G, half inch fixed needle \\nassembled in a patient-controlled injector containing 100 mg guselkumab, (100 mg/1 mL \\nin a 1 mL volume) packaged in a carton.\\n\\nTREMFYA®/TREMFYA One-Press® does not contain preservatives.\\n\\nThe TREMFYA®/TREMFYA One-Press® needle guard and plunger stopper are not made with \\nnatural rubber latex.\\n\\n7 WARNINGS AND PRECAUTIONS\\n\\nGeneral\\n\\nInfections\\n\\nTREMFYA®/TREMFYA One-Press® is a selective immunomodulatory agent which has the \\npotential to increase the risk of infection. Infections have been observed in clinical trials in \\nplaque psoriasis (23% vs 21% for placebo; ≤ 0.2% serious infections in both groups) and \\npsoriatic arthritis (21% in both TREMFYA® and placebo groups; ≤ 0.8% serious infections in \\nboth groups). The most common type of infection reported was respiratory tract infection. (See \\n8 ADVERSE REACTIONS, Infections)\\n\\nTreatment with TREMFYA®/TREMFYA One-Press® should not be initiated in patients with any \\nclinically important active infection until the infection resolves or is adequately treated. \\n\\nInstruct patients treated with TREMFYA®/TREMFYA One-Press® to seek medical advice if signs \\nor symptoms of clinically important chronic or acute infection occur. If a patient develops a \\nclinically important or serious infection or is not responding to standard therapy, monitor the \\npatient closely and discontinue TREMFYA®/TREMFYA One-Press® until the infection resolves.\\n\\nIn clinical studies, subjects with latent tuberculosis (TB) who were concurrently treated with \\nTREMFYA® and appropriate TB prophylaxis did not develop TB. Evaluate patients for TB \\ninfection prior to initiating treatment with TREMFYA®/TREMFYA One-Press®. Initiate treatment \\nof latent TB prior to administering TREMFYA®/TREMFYA One-Press®. Patients receiving \\nTREMFYA®/TREMFYA One-Press® should be monitored for signs and symptoms of active TB \\nduring and after treatment. Do not administer TREMFYA®/TREMFYA One-Press® to patients \\nwith active TB infection. Consider anti-TB therapy prior to initiating TREMFYA®/TREMFYA One-\\nPress® in patients with a past history of latent or active TB in whom an adequate course of \\ntreatment cannot be confirmed. \\n\\nImmune\\n\\nVaccinations\\n\\nPrior to initiating therapy with TREMFYA®/TREMFYA One-Press®, consider completion of all \\nage appropriate immunizations according to current immunization guidelines. Avoid use of live \\nvaccines in patients treated with TREMFYA®/TREMFYA One-Press® (see 9 DRUG \\nINTERACTIONS). No data are available on the response to live or inactive vaccines.\\n\\nTRE11082022CPM_SNDS 259046.docx\\nEDMS-ERI-121169578 v15.0\\n\\nPage 7 of 47\\n\\n\\x0cReproductive Health: Female and Male Potential\\n\\n\\uf0b7 Fertility\\n\\nThe effect of TREMFYA®/TREMFYA One-Press® on human fertility has not been evaluated. No \\nguselkumab-related effects on fertility parameters were identified in a female fertility study \\nconducted in guinea pigs. In a male guinea pig fertility study, total litter loss was observed in a \\nlimited subset of untreated females following administration of males with guselkumab at a \\nsubcutaneous dose of 100 mg/kg twice weekly (24-fold the human exposure). This observation \\nwas not repeated in a second male fertility study. No effects were observed at 25 mg/kg (Cmax \\nand AUClast values were 51- and 6-fold greater, respectively, than the human exposure) (see \\n16 NON-CLINICAL TOXICOLOGY).\\n\\nSerious hypersensitivity reactions, including anaphylaxis, have been reported in the \\npostmarketing setting. Some serious hypersensitivity reactions occurred several days after \\ntreatment with TREMFYA®, including cases with urticaria and dyspnea. If a serious \\nhypersensitivity reaction occurs, appropriate therapy should be instituted and administration of \\nTREMFYA®/TREMFYA One-Press® should be discontinued.\\n\\nSensitivity/Resistance\\n\\nHypersensitivity\\n\\n7.1 Special Populations\\n\\n7.1.1 Pregnant Women\\n\\nThe use of TREMFYA®/TREMFYA One-Press® in pregnant women has not been studied. The \\neffect of TREMFYA®/TREMFYA One-Press® on human pregnancy is unknown. Studies in \\ncynomolgus monkeys showed that guselkumab crosses the placental barrier. Fetal losses and \\nneonatal deaths occurred in the offspring of pregnant monkeys administered weekly \\nsubcutaneous injections of guselkumab from the beginning of organogenesis until parturition at \\nCmax and AUClast values that were 31- and 8-fold greater, respectively, than the human levels. A \\ndrug-related effect could not be ruled out. No adverse developmental effects were observed in \\nsurviving infants. Animal studies are not always predictive of human response, and therefore, \\nthe clinical significance of these findings is unknown (see 16 NON-CLINICAL TOXICOLOGY). \\n\\nWomen of childbearing potential should use adequate contraception while using \\nTREMFYA®/TREMFYA One-Press® and for at least 12 weeks after the last \\nTREMFYA®/TREMFYA One-Press® dose. TREMFYA®/TREMFYA One-Press® should be used \\nduring pregnancy only if the potential benefit justifies the potential risk to the fetus.\\n\\nTo monitor outcomes in women exposed to TREMFYA® during pregnancy, a pregnancy registry \\nhas been established. Healthcare professionals are encouraged to register patients and \\npregnant women are encouraged to enroll themselves by calling 1-877-311- 8972.\\n\\n7.1.2 Breast-feeding\\n\\nThere are no data on the presence of guselkumab in human milk, the effects on the breastfed \\ninfant, or the effects on milk production. Guselkumab was not detected in the milk of lactating \\ncynomolgus monkeys (see 16 NON-CLINICAL TOXICOLOGY). The developmental and health \\n\\nTRE11082022CPM_SNDS 259046.docx\\nEDMS-ERI-121169578 v15.0\\n\\nPage 8 of 47\\n\\n\\x0cbenefits of breastfeeding should be considered, as well as any potential adverse effects on the \\nbreastfed infant. \\n\\nThe safety and efficacy of TREMFYA®/TREMFYA One-Press® in pediatric patients have not \\nbeen evaluated.\\n\\n7.1.3 Pediatrics\\n\\n7.1.4 Geriatrics\\n\\nOf the 3406 plaque psoriasis and psoriatic arthritis patients exposed to TREMFYA®/TREMFYA \\nOne-Press® in Phase 2 and Phase 3 clinical trials, a limited number of patients were 65 years or \\nolder (n = 185, 5%) or 75 years and older (n=13, 0.4%). Thus data in these age groups are \\nlimited (see 10 CLINICAL PHARMACOLOGY). \\n\\n8 ADVERSE REACTIONS\\n\\n8.1 Adverse Reaction Overview\\n\\nThe most frequently reported adverse drug reaction (>10%) through the placebo-controlled \\nperiod of the phase 3 plaque psoriasis and psoriatic arthritis clinical trials in TREMFYA®-treated \\npatients was respiratory tract infections. \\n\\nIn the placebo-controlled period of the phase 3 studies in plaque psoriasis, the proportion of \\nTREMFYA®-treated patients who discontinued treatment due to adverse events was 1.3% \\n(11/823) compared to 0.9% (8/422) in placebo- treated patients. Serious adverse events were \\nreported in 1.9% (16/823) of TREMFYA®-treated patients and 1.4% (6/422) of placebo-treated \\npatients through 16 weeks.\\n\\nIn the placebo-controlled period of the phase 3 studies in psoriatic arthritis, the proportion of \\nTREMFYA®-treated patients who discontinued treatment due to adverse events was 1.7% \\n(13/748) compared to 1.9% (7/372) in placebo- treated patients. Serious adverse events were \\nreported in 2.0% (15/748) of TREMFYA®-treated patients and 3.2% (12/372) of placebo-treated \\npatients through 24 weeks.\\n\\nOverall, the safety profile was generally similar across indications.\\n\\n8.2 Clinical Trial Adverse Reactions\\n\\nBecause clinical trials are conducted under very specific conditions, the adverse reaction rates \\nobserved in the clinical trials may not reflect the rates observed in practice and should not be \\ncompared to the rates in the clinical trials of another drug. Adverse drug reaction information \\nfrom clinical trials is useful for identifying drug-related adverse events and for approximating \\nrates.\\n\\nThe safety profile of TREMFYA®/TREMFYA One-Press® is based on data from the Phase 2 \\n(PSO2001) and Phase 3 (VOYAGE 1, VOYAGE 2, NAVIGATE, and ORION) studies in plaque \\npsoriasis and the Phase 2 (PSA2001) and the Phase 3 (DISCOVER 1 and DISCOVER 2) \\nstudies in psoriatic arthritis. Of the 3406 TREMFYA®- and TREMFYA One-Press®-treated \\npatients, 2716 patients were exposed for at least 1 year, and 1917, 1482, 1393 and 950 patients \\nwere exposed for at least 2, 3, 4 and 5 years, respectively. Most patients (n=2516) received a \\n\\nTRE11082022CPM_SNDS 259046.docx\\nEDMS-ERI-121169578 v15.0\\n\\nPage 9 of 47\\n\\n\\x0cdosage regimen of 100 mg TREMFYA®/TREMFYA One-Press® as subcutaneous injection every \\n8 weeks. In the phase 3 psoriatic arthritis trials 725 patients (including placebo crossovers) \\nreceived a dosage regimen of 100 mg TREMFYA® as subcutaneous injection every 4 weeks. \\n\\nAdverse Drug Reactions in Plaque Psoriasis Trials\\n\\nTable 1 provides a summary of adverse reactions that occurred at a rate of at least 1% and at a \\nhigher rate in the TREMFYA® group than in the placebo group during the 16-week, placebo-\\ncontrolled period of the pooled clinical trials, VOYAGE 1 and VOYAGE 2.\\n\\nTable 1: Adverse reactions reported by ≥1% of patients through Week 16 in VOYAGE 1 \\n\\nand VOYAGE 2\\n\\nPlacebo\\nN = 422 \\nn (%)\\n\\nTREMFYA®a\\nN = 823\\nn (%) \\n\\nAdalimumabb\\nN = 581\\nn (%)\\n\\n4 (0.9%)\\n\\n13 (1.6%)\\n\\n7 (1.2%)\\n\\n12 (2.8%)\\n\\n37 (4.5%)\\n\\n42 (7.2%)\\n\\n54 (12.8%)\\n\\n118 (14.3%)\\n\\n80 (13.8%)\\n\\n4 (0.9%)\\n2 (0.5%)\\n\\n0\\n\\n11 (1.3%)\\n9 (1.1%)\\n\\n9 (1.1%)\\n\\n8 (1.4%)\\n8 (1.4%)\\n\\n3 (0.5%)\\n\\n9 (2.1%)\\n\\n22 (2.7%)\\n\\n11 (1.9%)\\n\\nGastrointestinal \\ndisorders\\n      Diarrhea\\nGeneral disorders and \\nadministration site \\nconditions\\n      Injection site reactionsc\\nInfections and \\nInfestations\\n      Upper respiratory \\ninfectionsd\\n      Gastroenteritise\\n      Herpes simplex \\ninfectionsf\\n      Tinea infectionsg\\nMusculoskeletal and \\nconnective tissue \\ndisorders\\n      Arthralgia\\nNervous system \\ndisorders\\n      Headacheh\\n\\n14 (3.3%)\\n\\n38 (4.6%)\\n\\n18 (3.1%)\\n\\na Subjects received 100 mg of TREMFYA® at Week 0, Week 4, and every 8 weeks thereafter; \\nb Subjects received adalimumab at 80 mg Week 0, 40 mg week 1 then 40 mg q2w thereafter \\nc Injection site reactions include injection site erythema, bruising, hematoma, hemorrhage, swelling, \\nedema, pruritus, pain,discoloration, induration, inflammation, and urticaria.\\nd Upper respiratory infections include nasopharyngitis, upper respiratory tract infection (URTI), \\npharyngitis, and viral URTI.\\ne Gastroenteritis includes gastroenteritis and viral gastroenteritis\\nf Herpes simplex infections include oral herpes, herpes simplex, genital herpes, genital herpes \\nsimplex, and nasal herpes simplex.\\ng Tinea infections include tinea pedis, tinea cruris, tinea infection, and tinea manuum infections.\\nh Headache includes headache and tension headache.\\n\\nTRE11082022CPM_SNDS 259046.docx\\nEDMS-ERI-121169578 v15.0\\n\\nPage 10 of 47\\n\\n\\x0cSafety profile through Week 264 in Plaque Psoriasis Trials  \\n\\nThrough week 48 of VOYAGE 1 and VOYAGE 2, the types and the frequency of the adverse \\nreactions in the TREMFYA®-treated patients were similar to those observed during the first 16 \\nweeks of treatment. \\n\\nAmong 1221 patients who were initially randomized to TREMFYA® or who crossed over from \\nplacebo, 1119 patients received open-label TREMFYA® in the uncontrolled extension periods of \\nVOYAGE 1 and VOYAGE 2. Through up to 5 years (N=1221; median duration of follow-up of \\n262.1 weeks [Range: 1-276]), the safety profile of TREMFYA® was consistent with that \\nobserved in the controlled periods of VOYAGE 1 and VOYAGE 2.\\n\\nAdverse Drug Reactions in Psoriatic Arthritis Trials\\n\\nTable 2 provides a summary of adverse reactions that occurred at a rate of at least 1% and at a \\nhigher rate in the TREMFYA® group than in the placebo group during the 24-week, placebo-\\ncontrolled period of the pooled clinical trials, DISCOVER 1 and DISCOVER 2.\\n\\nTable 2: Adverse reactions reported by ≥1% of patients through Week 24 in DISCOVER 1 \\n\\nand DISCOVER 2\\n\\nPlacebo\\nN = 372\\nn (%)\\n\\nTREMFYA®\\nq8wa\\nN = 375\\nn (%)\\n\\nTREMFYA®\\nq4wb\\nN = 373\\nn (%)\\n\\n3 (0.8%)\\n\\n6 (1.6%)\\n\\n4 (1.1%)\\n\\n1 (0.3%)\\n\\n5 (1.3%)\\n\\n3 (0.8%)\\n\\n45 (12.1%)\\n\\n46 (12.3%)\\n\\n52 (13.9%)\\n\\n17 (4.6%)\\n\\n31 (8.3%)\\n\\n32 (8.6%)\\n\\n3 (0.8%)\\n\\n7 (1.9%)\\n\\n7 (1.9%)\\n\\nGastrointestinal disorders\\n      Diarrhea\\nGeneral disorders and \\nadministration site \\nconditions\\n      Injection site reactionsc\\nInfections and Infestations\\n      Respiratory tract \\ninfectionsd\\nInvestigations\\n      Transaminases \\nincreasede\\n      Neutrophil count \\ndecreased f\\nNervous system disorders\\n      Headacheg\\n\\n3 (0.8%)\\n\\n8 (2.1%)\\n\\n7 (1.9%)\\n\\na Patients received 100 mg of TREMFYA® at Week 0, Week 4, and every 8 weeks thereafter \\nb Patients received 100 mg of TREMFYA® at Week 0, Week 4, and every 4 weeks thereafter \\nc Injection site reactions include injection site erythema, bruising, hematoma, hemorrhage, swelling, \\nedema, pruritus, pain, discoloration, induration, inflammation, and urticaria.\\nd Respiratory tract infections include nasopharyngitis, upper respiratory tract infection (URTI), \\nbronchitis, pharyngitis, and viral URTI.\\neTransaminases increased includes alanine aminotransferase increased, aspartate aminotransferase \\nincreased, hepatic enzyme increased, transaminases increased, liver function test abnormal, \\nhypertransaminasaemia\\nf Neutrophil count decreased includes neutrophil count decreased and neutropenia\\ng Headache includes headache and tension headache.\\n\\nTRE11082022CPM_SNDS 259046.docx\\nEDMS-ERI-121169578 v15.0\\n\\nPage 11 of 47\\n\\n\\x0cAmong the 1120 adult patients with active psoriatic arthritis from DISCOVER 1 and DISCOVER \\n2, who were initially randomized to TREMFYA® or placebo, 1074 patients (including those who \\ncrossed over from placebo) received TREMFYA® at or after week 24 in the double-blind, \\nuncontrolled active treatment periods of DISCOVER 1 and DISCOVER 2. Through 1 year in \\nDISCOVER 1 and 2 years in DISCOVER 2, the safety profile of TREMFYA® was consistent with \\nthat observed in the controlled periods.\\n\\nInfections\\n\\nInfections have been observed in clinical trials in plaque psoriasis (23% for TREMFYA® vs 21% \\nfor placebo; ≤ 0.2% serious infections in both groups) and psoriatic arthritis (21% in both \\nTREMFYA® and placebo groups; ≤ 0.8% serious infections in both groups).\\n\\nIn plaque psoriasis or psoriatic arthritis trials, adverse events of infection reported in ≥ 1% of \\npatients treated with TREMFYA® through the placebo-controlled period were respiratory tract \\ninfections, gastroenteritis, tinea infections, and herpes simplex infections. \\n\\nImmunogenicity\\n\\nAs with all therapeutic proteins, there is the potential for immunogenicity with TREMFYA®. The \\nimmunogenicity of TREMFYA® was evaluated using a sensitive and drug-tolerant immunoassay. \\nIn subjects with psoriasis in clinical trials (PSO2001, VOYAGE 1, VOYAGE 2, and NAVIGATE), \\napproximately 6% of patients treated with TREMFYA® developed antidrug antibodies in up to 52 \\nweeks of treatment. Of the patients who developed antidrug antibodies, approximately 7% had \\nantibodies that were classified as neutralizing which equates to 0.4% of all patients treated with \\nTREMFYA®. Among the 46 subjects who developed antibodies to guselkumab and had \\nevaluable data, 21 subjects exhibited lower trough levels of guselkumab, including one subject \\nwho experienced loss of efficacy after developing high antibody titers. However, antibodies to \\nguselkumab were generally not associated with changes in clinical response or development of \\ninjection-site reactions.\\n\\nIn patients with psoriatic arthritis in clinical trials, 2% (n=15) of patients treated with TREMFYA®\\ndeveloped antidrug antibodies in up to 24 weeks of treatment. Of these patients, 1 (7%) had \\nantibodies that were classified as neutralizing which equates to 0.1% of all psoriatic arthritis \\npatients treated with TREMFYA®. None developed injection site reactions through Week 24. \\nOverall, the small number of patients who were positive for antibodies to guselkumab limits \\ndefinitive conclusion of the effect of immunogenicity on the pharmacokinetics, safety, and \\nefficacy of guselkumab.\\n\\nThe detection of antibody formation is highly dependent on the sensitivity and specificity of the \\nassay. Additionally, the observed incidence of antibody (including neutralizing antibody) \\npositivity in an assay may be influenced by several factors including assay methodology, \\nsample handling, timing of sample collection, concomitant medications, and underlying disease. \\nFor these reasons, comparison of incidence of antibodies to TREMFYA® with the incidences of \\nantibodies to other products may be misleading.\\n\\nElevated Liver Enzymes\\n\\nDuring the placebo-controlled period of the plaque psoriasis clinical trials, adverse events of \\nincreases in liver enzymes were reported in 2.6% of TREMFYA® treated patients and 1.9% of \\nplacebo-treated patients. None of these events led to discontinuation of TREMFYA® treatment. \\n\\nTRE11082022CPM_SNDS 259046.docx\\nEDMS-ERI-121169578 v15.0\\n\\nPage 12 of 47\\n\\n\\x0cDuring the placebo-controlled period of the two phase 3 psoriatic arthritis clinical trials, \\nadverse events of transaminases increased (includes alanine aminotransferase (ALT) \\nincreased, aspartate aminotransferase (AST) increased, hepatic enzyme increased, \\ntransaminases increased, liver function test abnormal, and hypertransaminasaemia) were \\nreported more frequently in the TREMFYA®-treated patients (8.3% of q8w group, and 8.6% \\nof q4w group) than in the placebo-treated patients (4.6%). \\n\\nBased on laboratory assessments, an increased incidence of liver enzyme elevations was \\nobserved in patients treated with TREMFYA® q4w compared to patients treated with \\nTREMFYA® q8w or placebo. Most transaminase increases (ALT and AST) were ≤ 3 x upper \\nlimit of normal (ULN). Transaminase increases from > 3 to ≤ 5 x ULN and > 5 x ULN were low in \\nfrequency (Table 3). A similar pattern was observed through the end of the 2-year Phase 3 \\npsoriatic arthritis clinical study (DISCOVER 2). In most cases, the increase in transaminases \\nwas transient and did not lead to discontinuation of treatment.  \\n\\nTable 3: Frequency of patients with transaminase increases post-baseline in two Phase \\n\\nIII psoriatic arthritis clinical studies\\n\\nThrough Week 24a\\nPlacebo\\n\\nTREMFYA®\\n100 mg q8w\\nN=373d\\n\\nTREMFYA®\\n100 mg q4wc\\nN=371d\\n\\nN=370d\\n\\nThrough 1 Yearb\\nTREMFYA®\\n100 mg q8w\\nN=373d\\n\\nTREMFYA®\\n100 mg q4wc\\nN=371d\\n\\n35.0%\\n2.7%\\n1.1%\\n\\n30.0%\\n1.4%\\n0.8%\\n\\n28.2%\\n1.1%\\n0.8%\\n\\nALT\\n>1 to ≤3 x ULN\\n>3 to ≤ 5 x ULN\\n>5 x ULN\\nAST\\n>1 to ≤3 x ULN\\n>3 to ≤ 5 x ULN\\n>5 x ULN\\na placebo-controlled period\\nb patients randomized to placebo at baseline and crossed over to TREMFYA® are not included\\nc q4w dosing is not recommended in psoriatic arthritis patients\\nd number of patients with at least one post-baseline assessment for the specific laboratory test within \\nthe time period\\n\\n33.5%\\n1.6%\\n1.1%\\n\\n22.8%\\n2.9%\\n0.5%\\n\\n18.8%\\n1.6%\\n0.5%\\n\\n20.0%\\n0.5%\\n1.1%\\n\\n21.6%\\n1.6%\\n1.6%\\n\\n27.8%\\n3.8%\\n1.6%\\n\\n41.2%\\n4.6%\\n1.1%\\n\\n8.3\\n\\nLess Common Clinical Trial Adverse Reactions\\n\\nAdverse reactions that occurred at rates <1% in the TREMFYA® group during the placebo \\ncontrolled- period of the pooled plaque psoriasis and psoriatic arthritis clinical trials.\\n\\nInfections and Infestations: candida infections, gastroenteritis, herpes simplex infections, \\ntinea infections\\nNervous system disorders: migraine \\nSkin and subcutaneous tissue disorders: urticaria\\n\\n8.5 Post-Market Adverse Reactions\\n\\nThe following adverse reactions have been reported during post-marketing experience. \\nBecause these reactions are reported voluntarily from a population of uncertain size, it is not \\nalways possible to estimate their frequency reliably or establish a causal relationship to drug \\nexposure.\\n\\nTRE11082022CPM_SNDS 259046.docx\\nEDMS-ERI-121169578 v15.0\\n\\nPage 13 of 47\\n\\n\\x0cImmune System disorders: anaphylaxis, hypersensitivity \\nSkin and Subcutaneous Tissue Disorders: rash, urticaria\\n\\n9 DRUG INTERACTIONS\\n\\n9.4 Drug-Drug Interactions\\n\\nLive vaccines\\n\\nImmunosuppression Therapy\\n\\nLive vaccines should not be given while a patient is undergoing therapy with \\nTREMFYA®/TREMFYA One-Press® (see 7 WARNINGS AND PRECAUTIONS, Immune).\\n\\nThe safety and efficacy of TREMFYA®/TREMFYA One-Press® in combination with \\nimmunosuppressant drugs, including biologics, or with phototherapy, have not been evaluated.\\n\\nInteractions with CYP450 Substrates\\n\\nThe formation of cytochrome P450 (CYP) enzymes can be altered by increased levels of certain \\ncytokines (e.g., interleukin [IL]-1β, IL-6, tumor necrosis factor-alpha, and interferon) during \\nchronic inflammation.\\n\\nIn a Phase 1 drug-drug interaction study in subjects (N=12) with moderate to severe plaque \\npsoriasis, the results suggested a low potential for clinically relevant drug interactions between a \\nsingle SC dose of guselkumab and substrates metabolized by CYP3A4, CYP2C9, CYP2C19, \\nand CYP1A2. However, the results were highly variable and the interaction potential of \\nguselkumab with drugs metabolized by CYP2D6 cannot be ruled out. \\n\\nUpon initiation of TREMFYA® in patients who are receiving concomitant CYP450 substrates, \\nparticularly those with a narrow therapeutic index, consider monitoring for therapeutic effect or \\ndrug concentration and consider dosage adjustment as needed.\\n\\n9.5 Drug-Food Interactions\\n\\nInteractions with food have not been established.\\n\\n9.6 Drug-Herb Interactions\\n\\nInteractions with herbal products have not been established.\\n\\n9.7 Drug-Laboratory Test Interactions\\n\\nInteractions with laboratory tests have not been established.\\n\\n10 CLINICAL PHARMACOLOGY\\n\\n10.1 Mechanism of Action\\n\\nGuselkumab is a human IgG1λ monoclonal antibody (mAb) that binds selectively to the p19 \\nsubunit of interleukin 23 (IL-23) and inhibits its interaction with cell surface IL-23 receptor. IL-23 \\nis a naturally-occurring cytokine that is involved in normal inflammatory and immune responses. \\nGuselkumab inhibits the release of proinflammatory cytokines and chemokines (e.g. IL-17A, IL-\\n\\nTRE11082022CPM_SNDS 259046.docx\\nEDMS-ERI-121169578 v15.0\\n\\nPage 14 of 47\\n\\n\\x0c17F and IL-22). Levels of IL-23 are elevated in the skin of patients with plaque psoriasis.\\n\\n10.2 Pharmacodynamics\\n\\nIn clinical trials in patients with plaque psoriasis, guselkumab reduced serum levels of IL-17A, \\nIL-17F and IL-22 relative to pre-treatment levels based on exploratory analyses of these \\npharmacodynamic markers. \\n\\nIn Phase 3 studies in psoriatic arthritis, evaluated patients had elevated serum levels of the \\nacute phase proteins C-reactive protein, serum amyloid A and IL-6, and the Th17 effector \\ncytokines IL-17A, IL-17F and IL-22 at baseline. Exploratory analyses found serum levels of \\nthese proteins measured at Week 4 and Week 24 were decreased compared to baseline \\nfollowing guselkumab treatment.\\n\\nThe relationship between these pharmacodynamic markers and the mechanism(s) by which \\nguselkumab exerts its clinical effects is unknown.\\n\\n10.3 Pharmacokinetics\\n\\nGuselkumab exhibited linear pharmacokinetics in healthy subjects or patients with psoriasis \\nover a dose range from 10 mg to 300 mg following subcutaneous injections.\\n\\nThe pharmacokinetics of guselkumab in subjects with psoriatic arthritis was similar to that in \\nsubjects with plaque psoriasis. \\n\\nAbsorption:\\n\\nFollowing a single 100 mg subcutaneous injection in healthy subjects, guselkumab reached a \\nmean (± SD) maximum serum concentration (Cmax) of 8.09 ± 3.68 mcg/mL by approximately \\n5.5 days post dose.\\n\\nIn subjects with psoriasis, steady-state serum guselkumab concentrations were achieved by \\nWeek 20 following subcutaneous administrations of 100 mg guselkumab at Weeks 0 and 4, and \\nevery 8 weeks thereafter. The mean (± SD) steady-state trough serum guselkumab \\nconcentrations in two Phase 3 studies were 1.15 ± 0.73 mcg/mL and 1.23 ± 0.84 mcg/mL. \\n\\nIn subjects with psoriatic arthritis, following subcutaneous administration of 100 mg of \\nTREMFYA® at Weeks 0, 4, and every 8 weeks thereafter, mean (± SD) steady-state trough \\nserum guselkumab concentration was approximately 1.18 ± 0.87 mcg/mL. \\n\\nThe absolute bioavailability of guselkumab following a single 100 mg subcutaneous injection \\nwas estimated to be approximately 49% in healthy subjects.\\n\\nIn subjects with plaque psoriasis, apparent volume of distribution was 13.5 L.\\n\\nDistribution:\\n\\nMetabolism:\\n\\nThe exact pathway through which guselkumab is metabolized has not been characterized. As a \\nhuman IgG monoclonal antibody, guselkumab is expected to be degraded into small peptides \\nand amino acids via catabolic pathways in the same manner as endogenous IgG.\\n\\nTRE11082022CPM_SNDS 259046.docx\\nEDMS-ERI-121169578 v15.0\\n\\nPage 15 of 47\\n\\n\\x0cElimination:\\n\\nApparent clearance in subjects with plaque psoriasis was 0.516 L/day. Mean half-life (T1/2) of \\nguselkumab was approximately 17 days in healthy subjects and approximately 15 to 18 days in \\nsubjects with plaque psoriasis across studies.\\n\\nClearance and volume of distribution of guselkumab increase as body weight increases, based \\non population pharmacokinetic analyses. However, observed clinical trial data indicate that dose \\nadjustment for body weight is not warranted.\\n\\nPopulation pharmacokinetic analyses indicated that concomitant use of acetaminophen, \\nNSAIDs, oral corticosteroids and conventional DMARDs such as methotrexate, did not affect \\nthe clearance of guselkumab.\\n\\nSpecial Populations and Conditions\\n\\n\\uf0b7 Pediatrics: The safety and efficacy of guselkumab have not been established in \\n\\npediatric patients.\\n\\n\\uf0b7 Geriatrics: Of the 1384 plaque psoriasis patients exposed to TREMFYA® in phase 3 \\nclinical studies and included in the population pharmacokinetic analysis (pop PK), \\n70 subjects were 65 years of age or older, including 4 subjects who were 75 years of \\nage or older. Population pharmacokinetic analyses indicated there were no apparent \\nchanges in clearance estimate in subjects ≥ 65 years of age compared to subjects \\n< 65 years of age, suggesting no dose adjustment is needed for elderly patients. Of the \\n746 psoriatic arthritis patients exposed to TREMFYA® in phase III clinical studies and \\nincluded in the pop PK analysis, a total of 38 patients were 65 years of age or older, and \\nno patients were 75 years of age or older.\\n\\n\\uf0b7 Gender, Race, Age: The clearance of guselkumab was not impacted by sex, age, or \\n\\nrace.\\n\\n\\uf0b7 Hepatic Insufficiency: No specific study has been conducted to determine the effect of \\n\\nhepatic impairment on the pharmacokinetics of guselkumab.\\n\\n\\uf0b7 Renal Insufficiency: No specific study has been conducted to determine the effect of \\n\\nrenal impairment on the pharmacokinetics of guselkumab.\\n\\n11 STORAGE, STABILITY AND DISPOSAL\\n\\nTREMFYA®/TREMFYA One-Press® is sterile and preservative-free. Discard any unused portion \\nafter injection.\\n\\nStore in a refrigerator at 2ºC to 8ºC (36ºF to 46ºF). Do not freeze.\\n\\nStore in original carton until time of use. Protect from light. Do not shake.  \\n\\nKeep out of sight and reach of children.\\n\\n12 SPECIAL HANDLING INSTRUCTIONS\\n\\nFollowing administration of TREMFYA®/TREMFYA One-Press®, discard any unused portion. \\nThe product should be disposed of in a puncture resistant container. Patients or caregivers \\nshould be instructed on how to properly dispose of the product, and told not to reuse these \\nitems. \\n\\nTRE11082022CPM_SNDS 259046.docx\\nEDMS-ERI-121169578 v15.0\\n\\nPage 16 of 47\\n\\n\\x0cPART II: SCIENTIFIC INFORMATION\\n\\n13 PHARMACEUTICAL INFORMATION\\n\\nDrug Substance\\n\\nProper name:  guselkumab\\n\\nChemical name:  guselkumab\\n\\nMolecular formula and molecular mass:  Guselkumab is a fully human immunoglobulin IgG1λ \\nmAb with an average molecular weight of 146,613 Daltons\\n\\nPhysicochemical properties:  TREMFYA®/TREMFYA One-Press® (guselkumab injection) is a \\nclear and colorless to light yellow solution and essentially free of visible particulate material with \\na pH of approximately 5.8\\n\\nProduct Characteristics:\\n\\nTREMFYA® is supplied as a 100 mg/mL sterile solution in a single-dose 1 mL glass syringe with \\na fixed 27G, half inch needle assembled in a passive needle guard delivery system.\\n\\nTREMFYA One-Press® is supplied as a 100 mg/mL sterile solution in a single-dose 1 mL glass \\nsyringe with a fixed 27G, half inch needle assembled in a patient-controlled injector.\\n\\nTREMFYA®/TREMFYA One-Press® does not contain preservatives.\\n\\n14 CLINICAL TRIALS\\n\\n14.1 Clinical Trials by Indication\\n\\nPlaque Psoriasis\\n\\nTable 4: Summary of trial designs and patient demographics\\n\\nStudy #\\n\\nTrial design\\n\\nVOYAGE 1 A phase 3, \\nmulticenter, \\nrandomized, \\ndouble-blind, \\nplacebo and \\nactive comparator \\ncontrolled study\\n\\nDosage, route of \\nadministration and \\nduration\\n\\nGuselkumab (n=329)\\n100 mg SC\\nWeeks 0, 4 then q8w \\nPlacebo (n=174) SC Weeks \\n0, 4, 12 → guselkumab 100 \\nmg SC Week 16, 20 then \\nq8wa\\nAdalimumab (n=334) SC 80 \\nmg Week 0, 40 mg week 1 \\nthen 40 mg q2w.b\\n\\nTotal \\nnumber of \\nsubjects\\n\\n837\\n\\nMean age \\n(Range)\\n\\nGender\\n\\n43.7\\n(18-87)\\n\\nM=608\\nF=229\\n\\nTRE11082022CPM_SNDS 259046.docx\\nEDMS-ERI-121169578 v15.0\\n\\nPage 17 of 47\\n\\n\\x0cVOYAGE 2 A phase 3, \\nmulticenter, \\nrandomized, \\ndouble-blind, \\nplacebo and \\nactive comparator \\ncontrolled study\\n\\nGuselkumab (n=496)\\n100 mg SC\\nWeeks 0, 4, 12 and 20c\\nPlacebo (n=248) SC Weeks \\n0, 4, 12 → guselkumab 100 \\nmg SC Week 16, 20a\\nAdalimumab (n=248) 80 mg \\nWeek 0, 40 mg week 1 then \\n40 mg q2w.d\\n\\n992\\n\\n43.0\\n(18-74)\\n\\nM=692\\nF=300\\n\\na The placebo group crossed over to receive guselkumab at Weeks 16 and 20 then q8w\\nb All subjects, including those randomized to adalimumab at Week 0, received TREMFYA® 100 mg at \\nWeek 52 and every 8 weeks thereafter.\\nc Subjects randomized to TREMFYA® at Week 0 who were PASI 90 responders at Week 28 were re-\\nrandomized to either continue treatment with TREMFYA® maintenance therapy or withdrawal of \\ntherapy. \\nd PASI 90 non-responders at week 28 started to receive TREMFYA® at week 28 and then week 32 \\nand every 8 weeks thereafter.\\n\\nThe efficacy and safety of TREMFYA® was assessed in two Phase 3, multicenter, randomized, \\ndouble-blind studies (VOYAGE 1 and VOYAGE 2) in patients 18 years or older with moderate to \\nsevere plaque psoriasis (with or without psoriatic arthritis) defined by Investigator’s Global \\nAssessment (IGA) ≥ 3, a Body Surface Area (BSA) involvement ≥ 10%, and Psoriasis Area and \\nSeverity Index (PASI) score ≥ 12, and were candidates for systemic therapy or phototherapy for \\npsoriasis. Patients with guttate, erythrodermic, or pustular psoriasis were excluded from the \\nstudies. No concomitant antipsoriatic therapies were allowed during the studies.\\n\\nThe two pivotal studies (VOYAGE 1 and 2) evaluated the efficacy and safety of guselkumab for \\nthe treatment of subjects with moderate to severe plaque-type psoriasis and enrolled a total of \\n1829 patients who were randomized to placebo, TREMFYA®, or adalimumab.\\n\\nThe co-primary endpoints in VOYAGE 1 and VOYAGE 2 were the proportions of patients who \\nachieved an IGA score of cleared (0) or minimal (1) and the proportions of patients who \\nachieved a PASI 90 response at Week 16, comparing the TREMFYA® group and the placebo \\ngroup.\\n\\nThe IGA is a 5-category scale: 0 = cleared, 1 = minimal, 2 = mild, 3 = moderate, 4 = severe, that \\nindicates the physician’s overall assessment of psoriasis focusing on plaque \\nthickness/induration, erythema and scaling.\\n\\nOther endpoints included the proportions of patients who achieved an IGA score of cleared (0), \\na PASI 100, PASI 75 response and regional disease as measured by scalp-specific IGA (ss-\\nIGA). Patient-reported outcomes were assessed based on the Psoriasis Symptoms and Signs \\nDiary (PSSD) and Dermatology Life Quality Index (DLQI).\\n\\nBaseline disease characteristics were generally consistent across all treatment groups for the \\nstudy populations in VOYAGE 1 and 2 with a median BSA of 22% and 24%, a median baseline \\nPASI score of 19 for both studies, a baseline IGA score of severe for 25% and 23% of patients, \\nand a history of psoriatic arthritis for 19% and 18% patient, respectively.\\n\\nTRE11082022CPM_SNDS 259046.docx\\nEDMS-ERI-121169578 v15.0\\n\\nPage 18 of 47\\n\\n\\x0cOf all patients who were included in the VOYAGE 1 and VOYAGE 2 studies, 32% and 29% \\nwere naïve to conventional systemic and biologic systemic therapy; 54% and 57% had received \\nprior phototherapy, and 62% and 64% had received prior conventional systemic therapy, \\nrespectively. In both studies, 21% had received prior biologic systemic therapy, including 11% \\nwho had received at least one anti-tumour necrosis factor alpha (TNFα) agent, and \\napproximately 10% who had received an anti-IL-12/IL-23 agent.\\n\\nThe results of VOYAGE 1 and VOYAGE 2 studies are presented in Table 5 and Table 6 below.\\n\\nTable 5: Summary of Clinical Responses at Week 16 (NRIa) in Psoriasis Studies (Co-\\n\\nPrimary Endpoints)\\n\\nTREMFYA®\\n(N=329)\\nn (%)\\n280 (85%)c\\n\\nVOYAGE 1\\nPlacebo\\n(N=174)\\nn (%)\\n12 (7%)\\n\\nTreatment \\ndifferenceb\\n(95% CI)\\n78% \\n(73%,83%)\\n\\nVOYAGE 2\\n\\nTREMFYA®\\n(N=496)\\nn (%)\\n417 (84%)c\\n\\nPlacebo\\n(N=248)\\nn (%)\\n21 (8%)\\n\\nTreatment \\ndifferenceb\\n(95% CI)\\n76% (71%,80%)\\n\\n241 (73%)c\\n\\nIGA \\nresponse \\nof 0/1\\nPASI 90 \\nresponse\\na Non-responder imputation.\\nb Treatment difference versus placebo adjusted by investigator site with Mantel-Haenszel weights.\\nc p-value < 0.001; p-value is based on the Cochran-Mantel-Haenszel chi-square test stratified by \\ninvestigator site.\\n\\n70% \\n(65%,76%)\\n\\n347 (70%)c\\n\\n6 (2%)\\n\\n5 (3%)\\n\\n68% (64%,72%)\\n\\nTable 6: Summary of Clinical Responses (NRIa) in Psoriasis Studies (Secondary \\n\\nEndpoints)\\n\\nTREMFYA®\\n(N=329)\\nn (%)\\n\\nVOYAGE 1\\nAdalimumab\\n(N=334)\\nn (%)\\n\\nTreatment \\ndifferenceb\\n(95% CI)\\n\\nTREMFYA®\\n(N=496)\\nn (%)\\n\\nVOYAGE 2\\nAdalimumab\\n(N=248)\\nn (%)\\n\\nWeek 16\\n\\n280 (85%)c\\n\\n220 (66%)\\n\\n417 (84%)c\\n\\n168 (68%)\\n\\n206 (62%)\\n\\n414 (83%)c\\n\\n161 (65%)\\n\\n98 (29%)\\n\\n257 (52%)c\\n\\n78 (31%)\\n\\n244 (73%)\\n\\n428 (86%)c\\n\\n170 (69%)\\n\\nWeek 16\\n\\n241 (73%)c\\n\\n166 (50%)\\n\\n347 (70%)c\\n\\n116 (47%)\\n\\nWeek 24\\n\\n264 (80%)c\\na Non-Responder Imputation.\\nb Treatment difference versus adalimumab adjusted by investigator site with Mantel-Haenszel weights.\\n\\n373 (75%)c\\n\\n136 (55%)\\n\\n177 (53%)\\n\\nTRE11082022CPM_SNDS 259046.docx\\nEDMS-ERI-121169578 v15.0\\n\\nPage 19 of 47\\n\\nIGA response of 0/1 \\n\\nWeek 24\\nIGA response of 0 \\n\\n277 (84%)c\\n\\nWeek 24\\nPASI 75 response\\n\\n173 (53%)c\\n\\nWeek 16\\nPASI 90 response\\n\\n300 (91%)c\\n\\nTreatment \\ndifferenceb\\n(95% CI)\\n\\n16% \\n(11%,22%)\\n18% \\n(12%,25%)\\n\\n20% \\n(13%,27%)\\n\\n18% \\n(12%,24%)\\n\\n23% \\n(17%,30%)\\n20% \\n(14%,27%)\\n\\n19% \\n(13%,25%)\\n23% \\n(17%,29%)\\n\\n25% \\n(18%,31%)\\n\\n18% \\n(13%,23%)\\n\\n24% \\n(17%,31%)\\n28% \\n(22%,34%)\\n\\n\\x0cc p-value < 0.001; p-value is based on the Cochran-Mantel-Haenszel chi-square test stratified by \\ninvestigator site. Type 1 error rate is controlled based on a pre-defined hierarchical testing procedure.\\n\\nTREMFYA® demonstrated superiority to placebo for the co-primary endpoints of IGA cleared (0) \\nor minimal (1), and PASI 90 at week 16 (Table 5). \\n\\nIn addition, TREMFYA® demonstrated statistical superiority to adalimumab for IGA cleared or \\nminimal (0 or 1), PASI 90 and PASI 75 at week 16 and IGA cleared (0), IGA cleared or minimal \\n(0 or 1) and PASI 90 at week 24 (see Table 6). In VOYAGE 1, with continued treatment over 48 \\nweeks, IGA cleared (0), IGA cleared or minimal (0 or 1) and PASI 90 responses in guselkumab \\ntreated patients were maintained and remained significantly greater than those achieved with \\nadalimumab (IGA cleared (0), 50% vs 26%, IGA cleared or minimal (0 or 1), 81% vs 55%, PASI \\n90, 76% vs. 48%).\\n\\nIn the VOYAGE 1 study, at week 16, 37% of patients receiving TREMFYA® achieved PASI 100 \\ncompared to 17% of adalimumab treated patients, and 1% of placebo treated patients. In \\nVOYAGE 2, at Week 16, 34% of patients receiving TREMFYA® achieved PASI 100 compared to \\n21% of adalimumab treated patients, and 1% of placebo-treated patients.\\n\\nIn VOYAGE 1, among 494 patients randomized to TREMFYA® or who crossed over from \\nplacebo, 460 patients received open-label TREMFYA® in the uncontrolled extension period after \\nweek 48. At week 252, 76.9% (380/494) of patients remained on TREMFYA® and 66.6% \\n(329/494) achieved PASI 90.\\n\\nIn TREMFYA® treated-patients, improvement was seen in psoriasis involving the scalp (as \\nmeasured by the Scalp-specific Investigator Global Assessment [ss-IGA]). Specifically, in the \\nsubset of patients with a baseline ss-IGA score ≥ 2, 83.4% and 80.6% in the TREMFYA® group \\nin VOYAGE 1 and VOYAGE 2, respectively, achieved an ss-IGA score of 0 or 1 and at least a \\n2-grade improvement from baseline compared to 14.5% and 10.9% in the placebo group, \\nrespectively at week 16.  \\n\\nMaintenance and Durability of Response\\nTo evaluate the maintenance and durability of response, patients originally randomized to \\nTREMFYA® and who were PASI 90 responders at Week 28 in the VOYAGE 2 study were re-\\nrandomized to continue maintenance treatment with TREMFYA® or be withdrawn from therapy \\n(i.e., placebo). At week 48, 88.6% of patients in the continuous maintenance treatment group \\nwere PASI 90 responders compared with 36.8% in the withdrawal group. By week 72, 86.0% of \\npatients in the continuous maintenance treatment group were PASI 90 responders compared \\nwith 11.5% in the withdrawal group.\\n\\nPatient-reported Outcomes\\nSignificantly greater improvements in psoriasis symptoms (itch, pain, stinging, burning and skin \\ntightness) at Week 16 were seen in TREMFYA® compared to placebo in both studies based on \\nthe Psoriasis Symptoms and Signs Diary (PSSD). Significantly greater proportions of patients \\non TREMFYA® compared to adalimumab achieved a PSSD symptom score of 0 (symptom-free) \\nat Week 24 in both studies. \\n\\nImprovements in the Dermatology Life Quality Index (DLQI) from baseline were observed in \\n\\nTRE11082022CPM_SNDS 259046.docx\\nEDMS-ERI-121169578 v15.0\\n\\nPage 20 of 47\\n\\n\\x0cpatients treated with TREMFYA® compared to placebo at Week 16.\\n\\nActive-Controlled Study in Ustekinumab Inadequate Responders – NAVIGATE\\nThe NAVIGATE study evaluated the efficacy of 24 weeks of treatment with TREMFYA® in \\npatients (N=268) who had an inadequate response (defined as IGA ≥2) at Week 16 after initial \\ntreatment with ustekinumab (dosed at Week 0 and Week 4). These patients were randomized to \\neither continue ustekinumab treatment every 12 weeks or to switch to TREMFYA® 100 mg given \\nat Weeks 16, 20, and every 8 weeks thereafter. Baseline characteristics for randomized \\nsubjects were similar to those observed in VOYAGE 1 and VOYAGE 2. \\n\\nIn patients with an inadequate response to ustekinumab, a greater proportion of patients who \\nswitched to TREMFYA® treatment achieved an IGA score of 0 or 1 and had a ≥ 2-grade \\nimprovement at Week 28 compared to patients who continued ustekinumab treatment (31% vs \\n14%, respectively). \\n\\nTREMFYA One-Press® - ORION\\nORION evaluated the efficacy, safety, and PK of guselkumab administered with the patient-\\ncontrolled One-Press injector. In this study, 78 subjects were randomized to receive either \\nTREMFYA One-Press® (100 mg at Weeks 0 and 4 and every 8 weeks thereafter, N= 62), or \\nplacebo (N= 16). Baseline characteristics for randomized subjects were comparable to those \\nobserved in VOYAGE 1 and VOYAGE 2. The co-primary endpoints were the same as those for \\nVOYAGE 1 and VOYAGE 2. The secondary endpoints included the proportion of subjects who \\nachieved an IGA score 0 at Week 16 and the proportion of subjects who achieved a PASI 100 \\nresponse at Week 16. \\n\\nA greater proportion of subjects in the guselkumab group achieved an IGA score of 0 or 1 or a \\nPASI 90 response at Week 16 (81% and 76%, respectively) than in the placebo group (0% for \\nboth endpoints). The proportion of subjects who achieved an IGA score of 0 at Week 16 was \\nhigher in the guselkumab group compared to the placebo group (56.5% vs. 0%). The proportion \\nof subjects who achieved a PASI 100 response at Week 16 was higher in the guselkumab \\ngroup compared to the placebo group (50.0% vs. 0%).\\n\\nPsoriatic Arthritis\\n\\nTable 7: Summary of trial designs and patient demographics\\n\\nStudy #\\n\\nTrial design\\n\\nDISCOVER \\n1\\n\\nA phase 3, \\nmulticenter, \\nrandomized, \\ndouble-blind, \\nplacebo-\\ncontrolled study\\n\\nDosage, route of \\nadministration and \\nduration\\n\\nGuselkumab (n=127)\\n100 mg SC\\nWeeks 0, 4 then q8w \\nGuselkumab (n=128)\\n100 mg SC\\nWeeks 0, then q4w\\nPlacebo (n=126) SC Weeks \\n0, then q4w to week 20 → \\nguselkumab 100 mg SC \\nWeek 24, then q4w\\n\\nTotal \\nnumber of \\nsubjects \\n\\n381\\n\\nMean age \\n(Range)\\n\\nGender\\n\\n48.4\\n(19-74)\\n\\nM=195\\nF=186\\n\\nTRE11082022CPM_SNDS 259046.docx\\nEDMS-ERI-121169578 v15.0\\n\\nPage 21 of 47\\n\\n\\x0c739\\n\\n45.7\\n(19-75)\\n\\nM=388\\nF=351\\n\\nDISCOVER \\n2\\n\\nA phase 3, \\nmulticenter, \\nrandomized, \\ndouble-blind, \\nplacebo-\\ncontrolled study\\n\\nGuselkumab (n=248)\\n100 mg SC\\nWeeks 0, 4 then q8w \\nGuselkumab (n=245)\\n100 mg SC\\nWeeks 0, then q4w\\nPlacebo (n=246) SC Weeks \\n0, then q4w to week 20 → \\nguselkumab 100 mg SC \\nWeek 24, then q4w \\n\\nThe safety and efficacy of TREMFYA® were assessed in 1120 patients in 2 randomized, double-\\nblind, placebo-controlled studies (DISCOVER 1 and DISCOVER 2) in adult patients with active \\npsoriatic arthritis (≥3 swollen joints, ≥3 tender joints, and a C-reactive protein (CRP) level of \\n≥0.3 mg/dL in DISCOVER 1 and ≥5 swollen joints, ≥5 tender joints, and a CRP level of ≥0.6 \\nmg/dL in DISCOVER 2) who had inadequate response to standard therapies (e.g. conventional \\nDMARDs [cDMARDs]), apremilast, or nonsteroidal anti-inflammatory drugs [NSAIDs]). Patients \\nin these studies had a diagnosis of psoriatic arthritis for at least 6 months based on the \\nClassification criteria for Psoriatic Arthritis (CASPAR) and a median duration of psoriatic arthritis\\nof 4 years at baseline.\\n\\nIn DISCOVER 1 approximately 30% of patients had been previously treated with up to \\n2 anti-tumor necrosis factor alpha (anti-TNFα) agents whereas in DISCOVER 2 all patients were \\nbiologic naïve. Approximately 58% of patients from both studies had concomitant methotrexate \\n(MTX) use. Patients with different subtypes of psoriatic arthritis were enrolled in both studies, \\nincluding polyarticular arthritis with the absence of rheumatoid nodules (40%), spondylitis with \\nperipheral arthritis (30%), asymmetric peripheral arthritis (23%), distal interphalangeal \\ninvolvement (7%) and arthritis mutilans (1%). At baseline, over 65% and 42% of the patients \\nhad enthesitis and dactylitis, respectively and over 75% had ≥3% body surface area (BSA) \\npsoriasis skin involvement. The primary endpoint in both studies was the percentage of patients \\nachieving an ACR20 response at Week 24. \\n\\nSigns and Symptoms\\nThe ACR responses at week 24 are presented in Table 8 below. Comparable response rates \\nwere observed regardless of prior anti-TNFα exposure in DISCOVER 1, and in both trials \\ncomparable response rates were observed regardless of concomitant cDMARD use or previous \\ntreatment with cDMARDs.\\n\\nTable 8: Percent of Patients with ACR Responsesa,b at Week 24 in DISCOVER 1 and \\n\\nDISCOVER 2\\n\\nPlacebo\\n(N=126)\\n\\nACR 20 \\nresponse\\n\\n22.2%\\n\\nDISCOVER 1\\n\\nDISCOVER 2\\n\\nTREMFYA®\\n100 mg \\nq8w\\n(N=127)\\n52.0%\\n\\nDifference from \\nPlacebo (95% \\nCI)\\np-value\\n29.8%\\n(18.6, 41.1)\\n<0.001c\\n\\nPlacebo\\n(N=246)\\n\\n32.9%\\n\\nTREMFYA®\\n100 mg \\nq8w\\n(N=248)\\n64.1%\\n\\nDifference from \\nPlacebo (95% \\nCI)\\np-value\\n31.2%\\n(22.9, 39.5)\\n<0.001d\\n\\nPage 22 of 47\\n\\nTRE11082022CPM_SNDS 259046.docx\\nEDMS-ERI-121169578 v15.0\\n\\n\\x0cDISCOVER 1\\n\\nDISCOVER 2\\n\\nPlacebo\\n(N=126)\\n\\n8.7%\\n\\nTREMFYA®\\n100 mg \\nq8w\\n(N=127)\\n29.9%\\n\\nDifference from \\nPlacebo (95% \\nCI)\\np-value\\n\\nPlacebo\\n(N=246)\\n\\n14.2%\\n\\nTREMFYA®\\n100 mg \\nq8w\\n(N=248)\\n31.5%\\n\\nDifference from \\nPlacebo (95% \\nCI)\\np-value\\n\\n5.6%\\n\\n11.8%\\n\\n4.1%\\n\\n18.5%\\n\\nACR 50 \\nresponse\\nACR 70 \\nresponse\\n\\na Patients with <5% improvement from baseline in both tender and swollen joint counts at Week 16 \\nwere qualified for early escape and were permitted to initiate or increase the dose of concomitant \\nmedications including NSAIDs, oral corticosteroid and cDMARD, and remained on the randomized \\nstudy treatment. At Week 16, 19.0% and 3.1% (DISCOVER 1) and 15.4% and 5.2%, (DISCOVER 2) \\nof the patients in the placebo and TREMFYA® 100mg q8w groups respectively met early escape \\ncriteria.\\nb Patients with missing data at Week 24 were imputed as non-responders. Patients who initiated or \\nincreased the dose of cDMARD or oral corticosteroids over baseline, discontinued study or study \\nmedication, or initiated protocol prohibited medications/therapies for psoriatic arthritis prior to Week 24 \\nwere considered as treatment failures and non-responders. At Week 24, 16.7% and 5.5% (DISCOVER \\n1), and 6.9% and 4.8% (DISCOVER 2) of the patients in the placebo group and the TREMFYA® 100 \\nmg q8w group met treatment failure criteria. \\nc Treatment differences, 95% CIs and p-values were based on the Cochran-Mantel-Haenszel test \\nstratified by baseline non-biologic cDMARD and prior anti-TNFα agents.\\nd Treatment differences, 95% CIs and p-values were based on the Cochran-Mantel-Haenszel test \\nstratified by baseline non-biologic cDMARD and prior CRP (<2.0, ≥2.0 mg/dL).\\n\\nFigure 1: Percent of Patients Achieving ACR 20 Response by Visit Through Week 24 in \\nDISCOVER 2\\n\\nIn DISCOVER 1, among 127 patients randomized to TREMFYA® 100 mg q8w, 123 patients \\nreceived TREMFYA® at or after 24 weeks in the double-blind, uncontrolled active treatment \\n\\nTRE11082022CPM_SNDS 259046.docx\\nEDMS-ERI-121169578 v15.0\\n\\nPage 23 of 47\\n\\n\\x0cperiod. 91.3% (116/127) of patients remained on TREMFYA® at week 48 and 59.8% (76/127) \\nachieved ACR 20.\\n\\nIn DISCOVER 2, among 248 patients randomized to TREMFYA® 100 mg q8w, 240 patients \\nreceived TREMFYA® at or after 24 weeks in the double-blind, uncontrolled active treatment \\nperiod. 89.9% (223/248) of patients remained on TREMFYA® at week 100 and 73.8% (183/248) \\nachieved ACR 20.\\n\\nTable 9: Mean change from Baseline in ACR Component Scores at Week 24 Based on \\n\\nObserved Data\\n\\nDISCOVER 1\\n\\nDISCOVER 2\\n\\nPlacebo\\n(N=126)\\n\\nTREMFYA®\\n100 mg q8w\\n(N=127)\\n\\nPlacebo\\n(N=246)\\n\\nTREMFYA®\\n100 mg q8w\\n(N=248)\\n\\nNo. of Swollen Joints\\nBaseline\\nMean  change  at  Week \\n24\\nNo. of Tender Joints\\nBaseline\\nMean  change  at  Week \\n24\\nPatient’s Assessment of Pain\\nBaseline\\nMean  change  at  Week \\n24\\nPatient Global Assessment\\nBaseline\\nMean  change  at  Week \\n24\\nPhysician Global Assessment\\nBaseline\\nMean  change  at  Week \\n24\\nDisability Index (HAQ-DI)\\nBaseline\\nMean  change  at  Week \\n24\\nCRP (mg/dL)\\nBaseline\\nMean  change  at  Week \\n24\\n\\n10.1\\n-5.1\\n\\n19.8\\n-6.8\\n\\n5.8\\n-0.7\\n\\n6.1\\n-0.9\\n\\n6.3\\n-2.2\\n\\n1.2\\n-0.1\\n\\n1.4\\n-0.0\\n\\n10.9\\n-7.3\\n\\n20.2\\n-10.5\\n\\n6.0\\n-2.2\\n\\n6.5\\n-2.5\\n\\n6.2\\n-3.5\\n\\n1.2\\n-0.3\\n\\n1.6\\n-0.7\\n\\n12.3\\n-6.4\\n\\n21.6\\n-7.3\\n\\n6.3\\n-1.1\\n\\n6.5\\n-1.2\\n\\n6.7\\n-2.5\\n\\n1.3\\n-0.2\\n\\n2.1\\n-0.5\\n\\n11.7\\n-8.1\\n\\n19.8\\n-10.4\\n\\n6.3\\n-2.5\\n\\n6.5\\n-2.5\\n\\n6.6\\n-3.8\\n\\n1.3\\n-0.4\\n\\n2.0\\n-1.1\\n\\nIn patients with ≥3% BSA psoriasis skin involvement and an IGA score of ≥2 at baseline, the \\nproportion of patients who achieved a psoriasis response at week 24, defined as an IGA of 0 \\n(cleared) or 1 (minimal) and a ≥2-grade reduction from baseline, was assessed. In \\nDISCOVER 1, the proportions of patients achieving a psoriasis IGA response were 57.3% and \\n15.4% for the TREMFYA® 100mg q8w and placebo dose groups respectively. In DISCOVER 2, \\nthe proportions of these patients achieving a psoriasis IGA response were 70.5% and 19.1% for \\nthe TREMFYA® 100mg q8w and placebo dose groups respectively.\\n\\nTRE11082022CPM_SNDS 259046.docx\\nEDMS-ERI-121169578 v15.0\\n\\nPage 24 of 47\\n\\n\\x0cTreatment with TREMFYA® resulted in improvement in dactylitis and enthesitis in patients with \\npre-existing dactylitis or enthesitis at baseline.\\n\\nPhysical Function and Other Patient Reported Outcomes\\nAt week 24, a greater mean improvement from baseline in physical function, as measured by \\nthe Health Assessment Questionnaire-Disability Index (HAQ-DI) was shown in both studies in \\nthe TREMFYA® 100 mg q8w group compared to placebo. The mean change from baseline at \\nweek 24 was -0.32 and -0.073 (DISCOVER 1) and -0.37 and -0.13 (DISCOVER 2) for the \\nTREMFYA® 100mg q8w and placebo dose groups respectively (p<0.001 in both trials).  \\n\\nAt Week 24, patients in the TREMFYA® group in both DISCOVER 1 and DISCOVER 2 showed \\ngreater improvement from baseline in the SF-36 PCS compared with placebo. At Week 24 there \\nwas numeric improvement in the physical functioning, role-physical, bodily-pain, general health, \\nsocial-functioning and vitality domains but not in the role-emotional and mental health domains. \\nPatients in the TREMFYA® group in both DISCOVER 1 and DISCOVER 2 showed improvement \\nfrom baseline in fatigue measured with FACIT-fatigue at Week 24.\\n\\n16 NON-CLINICAL TOXICOLOGY\\n\\nGeneral Toxicology: In repeat-dose toxicity studies in cynomolgus monkeys, guselkumab was \\nwell-tolerated at weekly doses up to 50 mg/kg intravenously for 5 weeks or 50 mg/kg \\nsubcutaneously for up to 24 weeks. Additionally, there were no effects on cardiovascular, \\nrespiratory, and nervous system function, clinical pathology, or anatomical pathology \\nparameters. At the NOAEL (50 mg/kg once weekly), Cmax and AUClast values were \\napproximately 206-fold and 50-fold higher, respectively, than those following a single \\nadministration of a 100 mg SC dose to psoriasis patients (4.81 µg/mL and 108.48 µg•h/mL, \\nrespectively).\\n\\nCarcinogenicity and Genotoxicity: Studies have not been conducted to evaluate the \\ncarcinogenic or genotoxic potential of guselkumab.\\n\\nReproductive and Developmental Toxicology: In a combined embryo-fetal developmental \\nand pre- and post-natal development toxicity study, pregnant cynomolgus monkeys (19, 20, \\nand 20 in the 0, 10 and 50 mg/kg groups, respectively) were administered weekly subcutaneous \\ndoses of guselkumab from the beginning of organogenesis to parturition. Neonatal deaths \\noccurred in the offspring of 1 of 16 control monkeys and of 3 of 14 monkeys in each of the \\nguselkumab-administered groups (Cmax and AUClast values were 31- and 8-fold greater, \\nrespectively, than the human levels). These neonatal deaths were attributed to maternal \\nneglect, trauma, and early or late delivery, although a drug-related effect could not be ruled out. \\nFetal losses (spontaneous abortions, including stillbirths) were also observed at all dose levels, \\nall of which were within the historical control range for the testing facility, but for which a drug-\\nrelated effect could also not be ruled out. The clinical significance of these findings is unknown.  \\nNo guselkumab-related effects on functional or immunological development were observed in \\nthe infants from birth through 6 months of age.\\n\\nNo effects on fertility or early embryonic development were observed following administration of \\nfemale guinea pigs with guselkumab at subcutaneous doses up to 100 mg/kg twice-weekly \\nbefore mating, through mating, and during early gestation to implantation (Cmax and AUClast\\n\\nTRE11082022CPM_SNDS 259046.docx\\nEDMS-ERI-121169578 v15.0\\n\\nPage 25 of 47\\n\\n\\x0cvalues were 106- and 12-fold greater, respectively, than the human levels).\\nIn a male fertility and early embryonic development toxicity study conducted in guinea pigs, the \\nincidence of total litter loss (5 of 22 untreated females) was increased following administration of \\nmales with guselkumab at a subcutaneous dose of 100 mg/kg twice weekly prior to mating and \\nthrough mating for a total of 21 doses. In a second male fertility and early embryonic \\ndevelopmental toxicity study, there were no total litter losses in untreated females mated with \\ntreated males (100 mg/kg twice weekly). No effects on male fertility or early embryonic \\ndevelopment were observed at a dose of 25 mg/kg (Cmax and AUClast values were 51- and 6-fold \\ngreater, respectively, than the human levels). \\n\\nTRE11082022CPM_SNDS 259046.docx\\nEDMS-ERI-121169578 v15.0\\n\\nPage 26 of 47\\n\\n\\x0cPATIENT MEDICATION INFORMATION\\n\\nREAD THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE\\n\\nPrTREMFYA®\\nPrTREMFYA One-Press®\\n(guselkumab injection) \\nSolution for injection\\n100 mg/ 1 mL\\n\\nRead this carefully before you start taking TREMFYA®/TREMFYA One-Press® and each time \\nyou get a refill. This leaflet is a summary and will not tell you everything about this drug. Talk to \\nyour healthcare professional about your medical condition and treatment and ask if there is any \\nnew information about TREMFYA®/TREMFYA One-Press®. \\n\\nWhat is TREMFYA®/TREMFYA One-Press® used for?\\n\\n\\uf0b7 Plaque Psoriasis\\n\\nTREMFYA®/TREMFYA One-Press® is a prescription medicine used to treat adults with \\nmoderate to severe “plaque psoriasis”, an inflammatory condition affecting the skin and nails. \\nPlaque psoriasis can cause raised, thick, red and scaly patches (“psoriatic lesions”) that can \\nappear anywhere on your body. TREMFYA®/TREMFYA One-Press® reduces the inflammation \\nand other symptoms of the disease.\\n\\n\\uf0b7 Psoriatic Arthritis\\n\\nTREMFYA®/TREMFYA One-Press® is used to treat adults with active psoriatic arthritis. Psoriatic \\narthritis is an inflammatory disease of the joints, usually accompanied by psoriasis. Psoriatic \\narthritis can cause pain, swelling and stiffness in the joints, in addition to a disruption in daily \\nactivities and fatigue. If you have active psoriatic arthritis, you will be given \\nTREMFYA®/TREMFYA One-Press® alone or in combination with a conventional Disease \\nModifying Anti-Rheumatic Drug (cDMARD) such as methotrexate. TREMFYA®/TREMFYA One-\\nPress® reduces signs and symptoms of your arthritis and may improve symptoms in patients \\nthat have psoriasis.\\n\\nHow does TREMFYA®/TREMFYA One-Press® work?\\n\\nTREMFYA®/TREMFYA One-Press® contains the active substance guselkumab. Guselkumab is \\na monoclonal antibody. Monoclonal antibodies are proteins that recognize and bind specifically \\nto certain proteins in the body. This medicine works by neutralizing the activity of a protein \\ncalled IL-23, which is present at increased levels in diseases such as plaque psoriasis.\\n\\nUsing TREMFYA®/TREMFYA One-Press® should improve your skin clearance and reduce your \\nsymptoms of psoriasis such as itching, pain, stinging, burning and skin tightness. In addition, \\nTREMFYA®/TREMFYA One-Press® helps reduce the signs and symptoms of psoriatic arthritis.\\n\\nWhat are the ingredients in TREMFYA®/TREMFYA One-Press®?\\n\\nMedicinal ingredients: guselkumab\\n\\nTRE11082022CPM_SNDS 259046.docx\\nEDMS-ERI-121169578 v15.0\\n\\nPage 27 of 47\\n\\n\\x0cNon-medicinal ingredients: L-histidine, L-histidine monohydrochloride monohydrate, polysorbate \\n80, sucrose and water for injection.\\n\\nTREMFYA® comes in the following dosage forms:\\n\\n100mg/mL solution for injection in a single-dose pre-filled syringe\\n\\nTREMFYA One-Press® comes in the following dosage forms:\\n\\n100mg/mL solution for injection in a single-dose patient-controlled injector \\n\\nDo not use TREMFYA®/TREMFYA One-Press® if:\\n\\n\\uf0b7 You are allergic to guselkumab or any of the ingredients in TREMFYA®/TREMFYA One-\\n\\nPress®. See What are the ingredients in TREMFYA®/TREMFYA One-Press®.\\n\\nIf you think you are allergic, ask your healthcare professional for advice before using \\nTREMFYA®/TREMFYA One-Press®.\\n\\nTo help avoid side effects and ensure proper use, talk to your healthcare professional \\nbefore you take TREMFYA®/TREMFYA One-Press®. Talk about any health conditions or \\nproblems you may have, including if you:\\n\\n\\uf0b7\\n\\n\\uf0b7\\n\\uf0b7\\n\\n\\uf0b7\\n\\n\\uf0b7\\n\\n\\uf0b7\\n\\nare being treated for an infection or if you have an infection that does not go away or \\nkeeps coming back. TREMFYA®/TREMFYA One-Press® may lower your ability to fight \\ninfections and may increase your risk of infections.\\nhave tuberculosis (TB) or have been in close contact with someone with TB.\\nthink you have an infection or have symptoms of an infection such as\\n\\no fever or flu-like symptoms\\no muscle aches\\no cough\\no shortness of breath\\no burning when you urinate or urinating more often than normal\\no blood in your phlegm (mucus)\\no weight loss\\no warm, red or painful skin or sores on your body different from your psoriasis\\no diarrhea or stomach pain\\n\\nhave recently had a vaccination or if you are due to have a vaccination during treatment \\nwith TREMFYA®/TREMFYA One-Press®. You should not be given certain types of \\nvaccines (live vaccines) while using TREMFYA®/TREMFYA One-Press®.  \\nare pregnant, think that you may be pregnant or are planning to have baby. If you are a \\nwoman of childbearing potential, use adequate contraception while using \\nTREMFYA®/TREMFYA One-Press® and for at least 12 weeks after the last \\nTREMFYA®/TREMFYA One-Press® dose. Talk to your doctor about your contraception \\noptions.\\nare breast-feeding or plan to breast-feed. You and your doctor should decide if you will \\nbreast-feed while using TREMFYA®/TREMFYA One-Press®.\\n\\nLook out for infections and allergic reactions\\n\\n\\uf0b7 Do not use TREMFYA®/TREMFYA One-Press® if you have any symptoms of infection \\n\\nunless you are instructed by your healthcare provider.\\n\\nTRE11082022CPM_SNDS 259046.docx\\nEDMS-ERI-121169578 v15.0\\n\\nPage 28 of 47\\n\\n\\x0c\\uf0b7 After starting TREMFYA®/TREMFYA One-Press®, call your healthcare provider \\n\\nright away, if you have any of the symptoms of an infection listed above.\\n\\n\\uf0b7 Serious allergic reactions, which can include symptoms of a swollen face, lips, \\n\\nmouth, tongue or throat, difficulty swallowing or breathing, hives and shortness of \\nbreath, have occurred with TREMFYA®/TREMFYA One-Press®. Tell your doctor or \\nseek medical help immediately if you experience these symptoms.\\n\\nChildren and adolescents (below the age of 18 years) \\nTREMFYA®/TREMFYA One-Press® is not recommended for children and adolescents (under 18 \\nyears of age) because it has not been studied in this age group.\\n\\nTell your healthcare professional about all the medicines you take, including any drugs, \\nvitamins, minerals, natural supplements or alternative medicines.\\n\\nHow to take TREMFYA®/TREMFYA One-Press®:\\n\\nAlways use this medicine exactly as your healthcare professional has told you. Check with your \\nhealthcare professional if you are not sure.\\n\\nTREMFYA®/TREMFYA One-Press® is given by injection under your skin (subcutaneous \\ninjection).  \\n\\nYou and your healthcare professional should decide if you should inject TREMFYA®/TREMFYA \\nOne-Press® yourself. It is important not to try to inject yourself until you have been trained by \\nyour healthcare professional. A caregiver may also give you your TREMFYA®/TREMFYA One-\\nPress® injection after proper training.\\n\\nBefore use, remove TREMFYA®/TREMFYA One-Press® from the refrigerator. Keep \\nTREMFYA®/TREMFYA One-Press® inside the carton and allow it to reach room temperature by \\nwaiting for 30 minutes before injection. \\n\\nRead the “Instructions for Use” document carefully before using TREMFYA®/TREMFYA \\nOne-Press®.\\n\\nUsual dose:\\n\\nPlaque Psoriasis\\n\\nYour doctor will decide how much TREMFYA®/TREMFYA One-Press® you need and for how \\nlong.\\n\\n\\uf0b7 The dose is 100 mg (the contents of 1 pre-filled syringe or the contents of 1 patient-\\n\\ncontrolled injector) by subcutaneous injection. \\n\\n\\uf0b7 The first dose may be given by your healthcare provider.\\n\\n\\uf0b7 After the first dose, you will have the next dose 4 weeks later, and then every 8 weeks.  \\n\\nTRE11082022CPM_SNDS 259046.docx\\nEDMS-ERI-121169578 v15.0\\n\\nPage 29 of 47\\n\\n\\x0cPsoriatic Arthritis\\n\\n\\uf0b7 The dose is 100 mg (the contents of 1 pre-filled syringe or the contents of 1 patient-\\n\\ncontrolled injector) by subcutaneous injection.  \\n\\n\\uf0b7 The first dose may be given by your healthcare provider. \\n\\n\\uf0b7 After the first dose, you will have the next dose 4 weeks later, and then every 8 weeks \\n\\nTREMFYA®/TREMFYA One-Press® is for long-term treatment. Your healthcare professional will \\nregularly monitor your condition to check that the treatment is having the desired effect.\\n\\nYou should not stop using TREMFYA®/TREMFYA One-Press® unless you think it is causing a \\nsevere side effect. Speak to your doctor as soon as possible if this happens.  \\n\\nIf you accidentally inject more TREMFYA®/TREMFYA One-Press® than you should or the dose \\nhas been given sooner than prescribed, inform your healthcare professional.\\n\\nIf you think you have taken too much TREMFYA®/TREMFYA One-Press®, contact your \\nhealthcare professional, hospital emergency department or regional Poison Control Centre \\nimmediately, even if there are no symptoms.\\n\\nOverdose:\\n\\nMissed dose:\\n\\nIf you forget to take your TREMFYA®/TREMFYA One-Press® dose, inject a dose as soon as you \\nremember. Then, take your next dose at your regular scheduled time. If you are not sure what to \\ndo, contact your healthcare professional.\\n\\nWhat are possible side effects from using TREMFYA®/TREMFYA One-Press®?\\n\\nAs with all medicines, this medicine can cause side effects, although not everybody gets them. \\n\\nMost of the following side effects are mild to moderate. If any of these side effects becomes \\nsevere, tell your healthcare professional.\\n\\nSome side effects are very common (may affect more than 1 in 10 people)\\n\\nInfections of the nose, sinuses, or throat (e.g. common cold) or chest infections \\n(bronchitis)\\n\\nSome side effects are common (may affect up to 1 in 10 people):\\n\\n\\uf0b7 Redness, pain, irritation, swelling, bruising and/or itching at the injection site\\n\\n\\uf0b7\\n\\n\\uf0b7\\n\\n\\uf0b7\\n\\n\\uf0b7\\n\\n\\uf0b7\\n\\ndiarrhea \\n\\nheadache\\n\\njoint pain\\n\\nincreased level of liver enzymes in the blood\\n\\nTRE11082022CPM_SNDS 259046.docx\\nEDMS-ERI-121169578 v15.0\\n\\nPage 30 of 47\\n\\n\\x0cSome side effects are uncommon (may affect up to 1 in 100 people):\\n\\nstomach flu (gastroenteritis)\\n\\nherpes simplex infections (e.g. cold sores, genital herpes) \\n\\nfungal infections of the skin (e.g. athlete’s foot) \\n\\n\\uf0b7\\n\\n\\uf0b7\\n\\n\\uf0b7\\n\\n\\uf0b7\\n\\n\\uf0b7\\n\\n\\uf0b7\\n\\n\\uf0b7\\n\\n\\uf0b7 migraine\\n\\nyeast infections\\n\\nallergic reactions\\n\\nskin rash\\n\\ndecreased number of a type of white blood cell called neutrophils\\n\\nThese are not all the possible side effects you may feel when taking TREMFYA®/TREMFYA \\nOne-Press®. If you experience any side effects not listed here, contact your healthcare \\nprofessional. \\n\\nIf you have a troublesome symptom or side effect that is not listed here or becomes bad enough \\nto interfere with your daily activities, talk to your healthcare professional.\\n\\nReporting Side Effects\\n\\nYou can report any suspected side effects associated with the use of health products to \\nHealth Canada by:\\n\\n\\uf0b7 Visiting the Web page on Adverse Reaction Reporting\\n\\n(https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-\\ncanada.html) for information on how to report online, by mail or by fax; or\\n\\n\\uf0b7 Calling toll-free at 1-866-234-2345.\\n\\nNOTE: Contact your health professional if you need information about how to manage your \\nside effects. The Canada Vigilance Program does not provide medical advice.\\n\\nStorage:\\n\\nStore TREMFYA®/TREMFYA One-Press® in the refrigerator between 2°C to 8°C (36°F to 46°F).\\n\\nDo not freeze. Do not use if TREMFYA®/TREMFYA One-Press® has been frozen.\\n\\nDo not shake TREMFYA®/TREMFYA One-Press®.\\n\\nStore in original packaging to protect from light until use.\\n\\nKeep out of reach and sight of children.\\n\\nTRE11082022CPM_SNDS 259046.docx\\nEDMS-ERI-121169578 v15.0\\n\\nPage 31 of 47\\n\\n\\x0cDo not use TREMFYA®/TREMFYA One-Press®:\\n\\nif you notice that it is damaged or the seal is broken.\\n\\n\\uf0b7\\n\\n\\uf0b7\\n\\n\\uf0b7\\n\\nif the liquid is discoloured, cloudy or you can see large particles floating in it.\\n\\nafter the expiry date which is stated on the label and on the outer carton after “EXP.” \\n\\nTREMFYA®/TREMFYA One-Press® is for single use only. Ask your healthcare professional how \\nto throw away medicines no longer required.\\n\\nIf you want more information about TREMFYA®/TREMFYA One-Press®:\\n\\n\\uf0b7 Talk to your healthcare professional\\n\\n\\uf0b7 For questions or concerns, contact the manufacturer, Janssen Inc. \\n\\n(www.janssen.com/canada)\\n\\n\\uf0b7 Find the full product monograph that is prepared for healthcare professionals and \\nincludes this Patient Medication Information by visiting the Health Canada website\\nhttps://health-products.canada.ca/dpd-bdpp/index-eng.jsp; the manufacturer’s website \\nwww.janssen.com/canada, or by contacting the manufacturer at: 1-800-567-3331 or 1-\\n800-387-8781.\\n\\nThis leaflet was prepared by Janssen Inc., Toronto, Ontario, M3C 1L9.\\n\\nLast Revised: November 2022\\n\\n© 2022 JANSSEN Inc.\\n\\nAll trademarks used under license.\\n\\nTRE11082022CPM_SNDS 259046.docx\\nEDMS-ERI-121169578 v15.0\\n\\nPage 32 of 47\\n\\n\\x0cINSTRUCTIONS FOR USE (TREMFYA®)\\n\\nPrTREMFYA®\\n(guselkumab injection)\\n\\nPre-filled syringe\\n\\nSINGLE-DOSE\\n\\nPLEASE READ THESE INSTRUCTIONS BEFORE USE\\nImportant\\n\\nTREMFYA® comes as a single-dose pre-filled syringe containing one 100 mg dose. Each pre-\\nfilled syringe can be used only one time. Throw the used pre-filled syringe away (see Step 3) \\nafter each dose, even if there is medicine left in it. Do not reuse your pre-filled syringe. \\nIf your doctor decides that you or a caregiver may be able to give your injections of TREMFYA®\\nat home, you should receive training on the right way to prepare and inject TREMFYA® using \\nthe pre-filled syringe before attempting to inject.\\nRead this Instructions for Use document before using the TREMFYA® pre-filled syringe and \\neach time you get a refill. There may be new information. This instruction guide does not take \\nthe place of talking with your doctor about your medical condition or your treatment. Please also \\nread the Package Insert carefully and discuss any questions you may have with your doctor or \\nnurse.\\nThe TREMFYA® pre-filled syringe is intended for injection under the skin, not into the muscle or \\nvein. After injection, the needle will retract into the body of the device and lock into place.\\n\\nStorage information\\n\\nStore in refrigerator at 2° to 8°C. Do not freeze.\\n\\nKeep TREMFYA® and all medicines out of reach and sight of children.\\n\\nDo not shake the pre-filled syringe.\\n\\nTRE11082022CPM_SNDS 259046.docx\\nEDMS-ERI-121169578 v15.0\\n\\nPage 33 of 47\\n\\n\\x0cKeep TREMFYA® pre-filled syringe in the original carton to protect from light and \\nphysical damage.\\n\\nPre-filled syringe parts\\n\\nBefore injection\\n\\nTRE11082022CPM_SNDS 259046.docx\\nEDMS-ERI-121169578 v15.0\\n\\nPage 34 of 47\\n\\n\\x0cAfter injection\\n\\n• 1 Alcohol swab\\n• 1 Cotton ball or gauze pad\\n• 1 Adhesive bandage\\n• 1 Sharps container (See Step 3)\\n\\nTRE11082022CPM_SNDS 259046.docx\\nEDMS-ERI-121169578 v15.0\\n\\nPage 35 of 47\\n\\n\\x0c1. Prepare for your injection \\n\\nInspect carton\\nRemove carton with the pre-filled syringe from the refrigerator. \\nKeep the pre-filled syringe in the carton and let it sit on a flat surface at room temperature for at \\nleast 30 minutes before use.   \\nDo not warm any other way. \\nCheck the expiration date (‘EXP’) on the back panel of the carton. \\nDO NOT use if the expiration date has passed. \\nDo not inject TREMFYA® if the perforations on the carton are broken. \\nCall your doctor or pharmacist for a refill.\\n\\nChoose injection site\\nSelect from the following areas for your injection: \\n\\uf0b7 Front of thighs (recommended)\\n\\uf0b7 Lower abdomen\\n\\nDo not use the 2-inch (5-centimetre) area around belly-button.\\n\\n\\uf0b7 Back of upper arms (if a caregiver is giving you the injection)\\nDO NOT inject into skin that is tender, bruised, red, scaly or hard. \\nDo not inject into areas with scars or stretch marks.\\n\\nTRE11082022CPM_SNDS 259046.docx\\nEDMS-ERI-121169578 v15.0\\n\\nPage 36 of 47\\n\\n\\x0cClean injection site\\nWash your hands well with soap and warm water.\\nWipe your chosen injection site with an alcohol swab and allow it to dry.\\nDo not touch, fan or blow on the injection site after you have cleaned it.\\n\\nInspect liquid\\nTake the pre-filled syringe out of the carton.  \\nCheck the liquid in the viewing window. It should be clear to slightly yellow and may contain tiny \\nwhite or clear particles. You may also see one or more air bubbles. \\nThis is normal.\\nDo not inject if the liquid is cloudy or discolored, or has large particles. Call your doctor or \\npharmacist for a refill.\\n\\nTRE11082022CPM_SNDS 259046.docx\\nEDMS-ERI-121169578 v15.0\\n\\nPage 37 of 47\\n\\n\\x0c2. Inject TREMFYA® using the pre-filled syringe \\n\\nRemove needle cover\\nHold syringe by the body and pull needle cover straight off. \\nIt is normal to see a drop of liquid. \\nInject within 5 minutes of removing the needle cover.\\nDO NOT put needle cover back on, as this may damage the needle \\nor cause a needle stick injury.\\nDO NOT touch needle or let it touch any surface.\\nDO NOT use the TREMFYA® pre-filled syringe if it is dropped. Call your doctor or pharmacist \\nfor a refill.\\n\\nPosition fingers and insert needle\\nPlace your thumb, index and middle fingers directly under the finger flange, as shown.\\nDo not touch plunger or area above finger flange as this may cause the needle safety device to \\nactivate.\\nUse your other hand to pinch skin at the injection site. \\nPosition syringe at about a 45 degree angle to the skin.\\nIt is important to pinch enough skin to inject under the skin and not into the muscle.\\nInsert needle with a quick, dart-like motion.\\n\\nTRE11082022CPM_SNDS 259046.docx\\nEDMS-ERI-121169578 v15.0\\n\\nPage 38 of 47\\n\\n\\x0cRelease pinch and reposition hand\\nUse your free hand to grasp the body of the syringe. \\n\\nPress plunger\\nPlace thumb from the opposite hand on the plunger and press the plunger all the way down \\nuntil it stops. \\n\\nRelease pressure from plunger\\nThe safety guard will cover the needle and lock into place, \\nremoving the needle from your skin. \\n\\nTRE11082022CPM_SNDS 259046.docx\\nEDMS-ERI-121169578 v15.0\\n\\nPage 39 of 47\\n\\n\\x0c3. After your injection \\n\\nThrow the used pre-filled syringe away\\nPut your used syringe in a sharps disposal container right away after use.\\nDo not dispose in your household trash.\\nMake sure you dispose of the bin as instructed by your doctor or nurse when the container is \\nfull.\\n\\nCheck injection site\\nThere may be a small amount of blood or liquid at the injection site. Hold pressure over your \\nskin with a cotton ball or gauze pad until any bleeding stops.\\nDo not rub the injection site.\\nIf needed, cover injection site with a bandage.\\n\\nNeed Help?\\n\\nCall your doctor to talk about any questions you may have. For questions or concerns visit the \\nmanufacturer’s website www.janssen.com/canada, or call 1-800-567-3331 or 1-800-387-8781.  \\n\\nThis leaflet was prepared by Janssen Inc., Toronto, Ontario, M3C 1L9.\\n\\nLast Revised November 2019\\nAll trademarks used under license.\\n\\nTRE11082022CPM_SNDS 259046.docx\\nEDMS-ERI-121169578 v15.0\\n\\nPage 40 of 47\\n\\n\\x0cINSTRUCTIONS FOR USE (TREMFYA One-Press®)\\n\\nPrTREMFYA One-Press®\\n\\n(guselkumab injection)\\n\\npatient-controlled injector\\n\\nSINGLE-DOSE DEVICE\\n\\nImportant\\nTREMFYA One-Press® comes as a single-dose patient-controlled injector containing one 100 \\nmg dose. Each One-Press injector can only be used one time. Throw away (see Step 3) after \\neach dose, even if there is medicine left in it. Do not reuse your One-Press injector. \\nIf your doctor decides that you or a caregiver may be able to give your injections of TREMFYA\\nOne-Press® at home, you should receive training on the right way to prepare and inject \\nTREMFYA One-Press®.\\nPlease read these Instructions for use before using the TREMFYA One-Press® and each time \\nyou fill your prescription. There may be new information. This instruction guide does not take the \\nplace of talking with your doctor about your medical condition or your treatment.\\nPlease also read the Package Insert carefully before starting your injection and discuss any \\nquestions you may have with your doctor or nurse.\\n\\nStorage information\\n\\nStore in refrigerator at 2° to 8°C. Do not freeze.\\n\\nKeep TREMFYA One-Press® and all medicines out of reach and sight of children. \\n\\nDo not shake at any time.\\nKeep TREMFYA One-Press® in the original carton to protect from light and physical \\ndamage.\\n\\nTRE11082022CPM_SNDS 259046.docx\\nEDMS-ERI-121169578 v15.0\\n\\nPage 41 of 47\\n\\n\\x0cTREMFYA One-Press® at-a-glance\\n\\nYou will need these supplies:\\n• 1 Alcohol swab\\n• 1 Cotton ball or gauze pad\\n• 1 Adhesive bandage\\n• 1 Sharps container (See Step 3)\\n\\nTRE11082022CPM_SNDS 259046.docx\\nEDMS-ERI-121169578 v15.0\\n\\nPage 42 of 47\\n\\n\\x0c1. Prepare for your injection \\n\\nInspect carton\\nRemove carton with TREMFYA One-Press® from the refrigerator.\\nKeep TREMFYA One-Press® in the carton and let it sit on a flat surface at room temperature for \\nat least 30 minutes before use.\\nDo not warm any other way.\\nCheck the expiration date (‘EXP’) on the carton.\\nDo not use if the expiration date has passed.\\nDo not inject if perforations on the carton are broken.\\nCall your doctor or pharmacist for a new TREMFYA One-Press®.\\n\\nChoose injection site\\nSelect from the following areas for your injection:\\n\\uf0b7 Front of thighs (recommended)\\n\\uf0b7 Lower abdomen\\n\\nDo not use the 2-inch (5-centimetre) area around your belly-button. \\n\\n\\uf0b7 Back of upper arms (if a caregiver is giving you the injection)\\nDo not inject into skin that is tender, bruised, red, scaly, hard or has scars or stretch marks.\\n\\nTRE11082022CPM_SNDS 259046.docx\\nEDMS-ERI-121169578 v15.0\\n\\nPage 43 of 47\\n\\n\\x0cWash hands\\nWash your hands well with soap and warm water.\\n\\nClean injection site\\nWipe your chosen injection site with an alcohol swab and allow it to dry.\\nDo not touch, fan or blow on the injection site after you have cleaned it.\\n\\nInspect liquid in window\\nTake TREMFYA One-Press® out of the carton.\\nCheck the liquid in the window. It should be clear to slightly yellow and may contain tiny white or \\nclear particles. You may also see one or more air bubbles. This is normal.\\nDo not inject if the liquid is cloudy or discoloured, or has large particles. If you are uncertain, \\ncall your doctor or pharmacist for a new TREMFYA One-Press®.\\n\\nTRE11082022CPM_SNDS 259046.docx\\nEDMS-ERI-121169578 v15.0\\n\\nPage 44 of 47\\n\\n\\x0c2. Inject TREMFYA One-Press® using the patient-controlled injector\\n\\nTwist and pull off bottom cap\\nKeep hands away from the needle guard after the cap is removed.\\nInject within 5 minutes of removing the cap.\\nDo not put the cap back on, this could damage the needle.\\nDo not use the product if it is dropped after removing the cap.\\nCall your doctor or pharmacist for a new TREMFYA One-Press®.\\n\\nPlace on skin\\nPosition TREMFYA One-Press® straight onto the skin (about 90 degrees relative to injection \\nsite).\\n\\nPush handle straight down\\n\\nTRE11082022CPM_SNDS 259046.docx\\nEDMS-ERI-121169578 v15.0\\n\\nPage 45 of 47\\n\\n\\x0cMedication injects as you push. Do this at a speed that is comfortable for you.\\nDo not lift TREMFYA One-Press® during the injection. The needle guard will lock and the full \\ndose will not be delivered.\\n\\nComplete injection\\nInjection is complete when the handle is pushed all the way down, you hear a click, and the teal \\nbody is no longer visible.\\n\\nLift straight up\\nThe yellow band indicates that the needle guard is locked.\\n\\n3. After your injection \\n\\nThrow the used product away\\n\\nTRE11082022CPM_SNDS 259046.docx\\nEDMS-ERI-121169578 v15.0\\n\\nPage 46 of 47\\n\\n\\x0cPut your used product in a sharps disposal container right away after use.\\nMake sure you dispose of the bin as instructed by your doctor or nurse when the container is \\nfull.\\n\\nCheck injection site\\nThere may be a small amount of blood or liquid at the injection site. Hold pressure over your \\nskin with a cotton ball or gauze pad until any bleeding stops. Do not rub the injection site.\\nIf needed, cover injection site with a bandage.\\n\\nNeed Help?\\n\\nCall your doctor to talk about any questions you may have. For questions or concerns visit the \\nmanufacturer’s website www.janssen.com/canada, or call 1-800-567-3331 or 1-800-387-8781. \\n\\nThis leaflet was prepared by Janssen Inc., Toronto, Ontario, M3C 1L9.\\n\\nLast Revised: November 2019\\nAll trademarks used under license.\\n\\nTRE11082022CPM_SNDS 259046.docx\\nEDMS-ERI-121169578 v15.0\\n\\nPage 47 of 47\\n\\n\\x0c'"
      ]
     },
     "execution_count": 7,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "doc.text"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "This is a sentence.This is another sentence.\n",
      "This is a paragraph.And another sentence in the same paragraph.\n"
     ]
    }
   ],
   "source": [
    "import re\n",
    "def replace_newlines(text):\n",
    "    # Define a regular expression pattern to match newline characters not followed by a space\n",
    "    pattern = re.compile(r'\\n(?!\\s)')\n",
    "    \n",
    "    # Replace newline characters matching the pattern with an empty string\n",
    "    cleaned_text = pattern.sub('', text)\n",
    "    \n",
    "    return cleaned_text\n",
    "\n",
    "# Example usage\n",
    "parsed_text = \"This is a sentence.\\nThis is another sentence.\\n\\nThis is a paragraph.\\nAnd another sentence in the same paragraph.\"\n",
    "cleaned_text = replace_newlines(parsed_text)\n",
    "print(cleaned_text)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": ".env",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.1"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
